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Summary 
Alcohol and other drug (AOD) treatment services across Australia provide a broad range of 
treatment services and support to people using drugs and to their families and friends. This 
report presents the information for 2013–14 about publicly funded AOD treatment service 
agencies, the people they treat and the treatment provided.  
Around 119,000 clients received over 180,000 treatment episodes from 795 publicly funded 
AOD treatment agencies across Australia 
An estimated 118,741 clients received treatment in 2013–14. This equates to a rate of 509 
clients per 100,000 people, or about 1 in 200 people in the general population. About 2 in 3 
clients were male (67%) and 1 in 2 were aged 20–39 (54%). Despite only comprising 2.7% of 
the population, 1 in 7 (14%) clients were Aboriginal and Torres Strait Islander.  
Treatment agencies provided a total of 180,713 treatment episodes—an average of 1.5 
episodes per client—and 4 in 5 (79%) episodes ended within 3 months. There has been a 
steady increase in the number of treatment episodes provided over the last 5 years (from 
145,630 to 180,713), an increase of 24%. Between 2012–13 and 2013–14, the estimated number 
of clients who received treatment increased by 8%. Of those clients who received treatment 
in 2013–14, 22% also received treatment in 2012–13. 
The age profile of people receiving treatment suggests there is an ageing cohort of clients 
Over the 5 years to 2013–14, the proportion of treatment episodes for clients who were aged 
20–29 fell from 29% to 27%, while the proportion for those aged 40 and over rose from 30% to 
33%. 
Alcohol continues to be the most common drug leading clients to seek treatment but 
treatment for use of amphetamines is increasing 
Alcohol, cannabis, amphetamines and heroin have remained the most common principal 
drugs of concern for clients since 2003–04. Nationally, alcohol was the most common 
principal drug of concern in 2013–14, accounting for 40% of episodes. For clients aged 30 and 
over, alcohol was the most common principal drug of concern, while for clients aged 10–29, 
cannabis was the most common. 
Since 2009–10, the proportion of episodes where alcohol was the most common principal 
drug of concern has decreased (from 48% to 40%), while the proportion of episodes for 
amphetamines have increased (from 7% to 17%). The number of episodes for clients injecting 
and smoking/inhaling amphetamines has also increased, with more than 6 times as many 
clients smoking/inhaling in 2013–14 as in 2009–10. 
Most clients have more than 1 drug of concern 
In more than half (54%) of treatment episodes, the client also reported additional drugs of 
concern. Just under a third (29%) had 1 additional drug of concern and 13% had 2 drugs. 
Nicotine and cannabis were the most common additional drugs of concern. 
Counselling continues to be the most common type of treatment 
Since 2003–04, the proportion of episodes for each main treatment type has remained fairly 
stable, with counselling, withdrawal management and assessment only being the most 
common types of treatment. Counselling continues to be the most common main treatment 
type provided for clients (2 in 5 episodes since 2003–04).
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1 Introduction 
AOD treatment services assist people to address their drug use through a range of 
treatments. Many types of treatment are available in Australia. Most aim to reduce the harm 
of drug use, while some use a structured drug-free setting with abstinence-oriented 
interventions to help prevent relapse and develop skills and attitudes that assist clients to 
make changes leading to drug-free lifestyles (AIHW 2011). 
1.1 Drug use in Australia 
Drug use can be either licit or illicit. ‘Licit drug use’ refers to the use of legal drugs in a legal 
manner, and includes tobacco smoking and alcohol consumption. ‘Illicit drug use’ refers to a 
number of broad concepts including the: 
• use of illegal drugs—a drug that is prohibited from manufacture, sale or possession in 
Australia, for example, cannabis, cocaine, heroin and ecstasy 
• misuse, non-medical or extra-medical use of pharmaceuticals—drugs that are available 
from a pharmacy, over-the-counter or by prescription, which may be subject to misuse, 
for example, opioid-based pain relief medications, opioid substitution therapies, 
benzodiazepines, over-the-counter codeine and steroids 
• use of other psychoactive substances—legal or illegal, potentially used in a harmful way, 
for example, kava, or inhalants such as petrol, paint or glue (but not including tobacco or 
alcohol) (MCDS 2011). 
Licit and illicit use of drugs is a significant issue in Australia and has a substantial societal 
cost estimated at $56 billion in 2004–05, of which $8 billion was for illicit drug use (Collins & 
Lapsley 2008). The 2013 National Drug Strategy Household Survey (NDSHS) found that 
alcohol and tobacco were the most common drugs used in Australia, with 78% of Australians 
aged 14 and over drinking alcohol in the previous 12 months and 13% smoking tobacco daily 
(AIHW 2014). Nearly 1 in 5 (18%) people drank at levels that put them at increased risk of 
harm over their lifetime (more than 2 standard drinks per day on average), while 26% of 
people drank at least once a month at levels that put them at risk of accident or injury (more 
than 4 standard drinks in a session). 
Although less prevalent than the use of licit drugs, illicit drug use is still relatively common. 
In 2013, about 2 in 5 people (42%) aged 14 and over reported using illicit drugs in their 
lifetime, while 1 in 7 (15%) reported using illicit drugs within the previous 12 months (AIHW 
2014). Cannabis was the most commonly used illicit drug; 1 in 3 (35%) Australians aged 14 
and over had used cannabis in their lifetime, while 1 in 10 (10%) had used it in the previous 
12 months. Ecstasy and hallucinogens were the second and third most common (11% and 
9%, respectively), while pain killers (analgesics) for non-medical purposes and ecstasy were 
the second and third most common for use in the previous 12 months (3% and 2%, 
respectively). 
1.2 National Drug Strategy 
Australia has had a coordinated approach to alcohol and other drugs since 1985. The 
National Drug Strategy 2010–2015, is the latest cooperative strategy between the Australian 
Government, state and territory governments and the non-government sector. It has an 
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overarching approach of harm minimisation and encompasses 3 pillars, each with specific 
objectives (MCDS 2011): 
• demand reduction to prevent and reduce the use of drugs, support people to recover 
from dependence and support efforts to promote social inclusion and resilient 
individuals, families and communities 
• supply reduction to reduce the supply of illegal drugs and control and manage the 
supply of alcohol, tobacco and other legal drugs 
• harm reduction to reduce harms to individuals, families and community safety. 
Harm reduction actions in the strategy include enhancing treatment ‘across settings to 
provide help at all stages of drug use, particularly for disadvantaged populations’, 
preventing drug overdoses through the use of ‘substitution therapies, withdrawal treatment 
and other pharmacotherapies’ and continuing drug diversion programs (MCDS 2011). 
1.3 Agencies, clients and treatment 
In Australia, publicly funded treatment services for AOD use are available in all states and 
territories. Most of these services are funded by state and territory governments while some 
are funded by the Australian Government.  
This report presents information on clients and treatment episodes delivered by publicly 
funded treatment agencies for AOD use from the AODTS NMDS. It does not include 
information on agencies that provide: 
• services primarily concerned with health promotion or accommodation 
• private treatment agencies that do not receive public funding 
• needle and syringe programs. 
Other available data sources that support a more complete picture of AOD treatment in 
Australia include: the National Opioid Pharmacotherapy Statistics Annual Data collection 
<http://www.aihw.gov.au/alcohol-and-other-drugs/nopsad/>, the National Hospital 
Morbidity Database, Online Services Report Database, Specialist Homelessness Services 
collection and the National Prisoner Health Data collection. Relevant data from these 
collections will be available online in a subsequent release later in 2015. 
Services are provided to people who are seeking assistance for their own drug use and those 
seeking assistance for someone else’s drug use. Two types of clients are included in this 
report: distinct and imputed. Distinct clients refer to those closed treatment episodes for 
which a valid statistical linkage key (SLK) has been supplied. Imputed client numbers have 
been estimated based on closed treatment episodes with and without a valid SLK (refer to 
Appendix B for further details on the imputation methodology). 
Information on clients and treatment services are included in the AODTS NMDS when a 
treatment episode provided to a client is closed. The following types of treatment are 
examined in this report: assessment only, counselling, information and education only, 
pharmacotherapy, rehabilitation, support and case management only and withdrawal 
management (see the Glossary for definitions). 
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1.4 The AODTS NMDS 
As a part of government efforts to report regularly on the status, quality and performance of 
the healthcare system, the 2012 National Healthcare Agreement (COAG 2012) mandates the 
collection of data for several National Minimum Data Sets, one of which is the Alcohol and 
Other Drug Treatment Services National Minimum Data Set (AODTS NMDS). This 
information is used to inform policy and help improve service delivery. 
The AODTS NMDS contains information on treatment episodes provided by publicly 
funded AOD treatment services, including government and non-government organisations. 
The main counting unit is closed treatment episodes, which is defined as a period of contact 
between a client and a treatment provider (or team of providers) that is closed when 
treatment is completed, there has been no further contact between the client and the 
treatment provider for 3 months, or treatment is ceased. Further details on the scope of the 
AODTS NMDS can be found online <http://www.aihw.gov.au/alcohol-and-other-
drugs/aodts/aodts-nmds/>. 
Data are collected by treatment agencies who forward these data to state and territory 
government health departments. These departments extract required data according to 
definitions and technical specifications agreed to by the departments and the Australian 
Institute of Health and Welfare (AIHW). Agencies funded by the Australian Government 
through the Non-Government Organisation Treatment Grants Program (NGOTGP) 
generally forward data directly to the AIHW. Data are submitted to the AIHW on an annual 
basis for national collation and reporting. 
The AODTS NMDS does not contain a unique identifier for clients and information about 
clients is collected at the episode level. For the 2012–13 collection, a statistical linkage key 
(SLK) was introduced. While the SLK is not a unique identifier, it enables the number of 
clients receiving treatment to be counted, while continuing to ensure their privacy. As SLK 
data are not available for all clients, an imputation strategy has been developed to estimate 
the number of clients and facilitate reporting at the client level. Further information about 
the imputation methodology applied to these data can be found in Appendix B. 
Coverage and data quality 
It is difficult to fully quantify the scope of AOD services in Australia. Until the 2012–13 
reference year, the AODTS NMDS has been based on counts of treatment episodes and 
counts of individual clients were not available. In addition, there are a variety of settings in 
which people receive treatment for alcohol or other drug-related issues that are not in scope 
for this collection.  
Agencies are excluded from the AODTS NMDS if they: 
• do not receive any public funding 
• primarily provide accommodation or overnight stays as their main function (for 
example, half-way houses and sobering-up shelters) 
• are based in prisons or other correctional institutions 
• provide services primarily concerned with health promotion (for example, needle and 
syringe programs) 
• are located in acute care or psychiatric hospitals and provide treatment only to admitted 
patients 
 4 Alcohol and other drug treatment services in Australia 2013–14 
• have the sole function of prescribing or providing dosing services for opioid 
pharmacotherapy (these agencies are excluded because of the multi-faceted nature of 
service delivery in this sector, however these data are captured in the AIHW’s National 
Opioid Pharmacotherapy Statistics Annual Data collection 
<http://www.aihw.gov.au/alcohol-and-other-drugs/nopsad/>). 
Australian Government-funded primary health care services and substance-use services 
specifically aimed at Indigenous Australians are in scope for the AODTS NMDS, but most of 
these agencies do not contribute to the collection as they currently provide data to the Online 
Services Report (OSR) collection. To minimise reporting burden, agencies reporting to the 
OSR do not usually also report to the AODTS NMDS (see online 
<http://www.aihw.gov.au/publication-detail/?id=60129550843> for the latest OSR report). 
In 2013–14, over 97% of in-scope agencies submitted data to the AODTS NMDS in all 
jurisdictions. Overall, there was an increase of 9.4 percentage points since 2012–13 in the 
number of in-scope agencies that reported to the collection.  
Several factors can contribute to changes in the number of agencies reporting between years. 
As well as changes in the number of in-scope agencies, some jurisdictions may change data 
collection approaches, for example, moving from collecting data at an administrative or 
management level to a service outlet level. 
Data are affected by variations in service structures and collection practices between states 
and territories and care should be taken when making comparisons between jurisdictions. In 
addition, the AODTS NMDS has been implemented in stages and comparisons across years, 
particularly the earlier years of the collection, should be made with caution.  
The AODTS NMDS reports on both main and additional treatment types. However, Victoria 
and Western Australia do not differentiate between main and other treatment types. Caution 
should be used in comparing episodes from these states with those of other states and 
territories. Despite variations in reporting practices between jurisdictions, there is very little 
difference between the proportions for principal drug of concern and all drugs of concern 
when these 3 jurisdictions are excluded from the analysis. For example, the top four drugs of 
concern remain the same in relative size and order. 
Further details on scope, coverage and data quality is available from the Data Quality 
Statement <http://meteor.aihw.gov.au/content/index.phtml/itemId/606485> for the 
AODTS NMDS and online <http://www.aihw.gov.au/alcohol-and-other-
drugs/aodts/aodts-nmds/>. 
1.5 Report structure 
Chapter 1 (this chapter) provides background information about AOD treatment services in 
Australia, the AODTS NMDS, and the context in which these data are reported. 
Chapter 2 provides an overview of findings from the 2013–14 AODTS NMDS. 
Chapter 3 presents data on AOD treatment agencies. 
Chapter 4 provides information on the drugs of concern people receive treatment for. 
Chapter 5 examines the type of treatment provided, including the characteristics of clients 
and episodes, and the type and outcome of treatment. 
Two appendixes are included in this report: 
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• Appendix A—Information about the data and methods 
• Appendix B—Imputation methodology for AODTS clients. 
The following online information accompanies this report: 
• scope, coverage and data quality <http://www.aihw.gov.au/alcohol-and-other-
drugs/aodts/aodts-nmds/> 
• data quality statement 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/606485> 
• state and territory summaries http://www.aihw.gov.au/publication-
detail/?id=60129551120 
• supplementary tables (those with a prefix of ‘S’ in the report) 
http://www.aihw.gov.au/publication-detail/?id=60129551120. 
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2 At a glance 
This chapter provides an overview of results from the AODTS NMDS for 2013–14. 
2.1 Key facts 
In 2013–14: 
• A total of 795 publicly funded agencies provided data about services for clients seeking 
treatment services and support. 
• An estimated 118,741 clients received treatment. 
• Most clients (86%) received treatment at 1 agency. 
• About 2 in 3 clients were male (67%) and half were aged 20–39 (54%). 
• Treatment agencies provided a total of 180,713 closed treatment episodes. 
• The main drugs that led clients to seek treatment were alcohol, cannabis, 
amphetamines and heroin (which was consistent for Indigenous and non-Indigenous 
clients), and for the majority of these, clients received treatment in a non-residential 
facility. 
• Counselling was the most common treatment type (43%). 
• 4 in 5 (79%) closed treatment episodes ended within 3 months. 
Over the 5-year period to 2013–14: 
• The number of publicly funded agencies providing data about services for clients 
seeking treatment services and support increased by 19%. 
• The number of closed treatment episodes increased from 145,630 to 180,713 (a 24% 
increase). 
• Alcohol continued to be the most common drug leading clients to seek treatment. 
• Treatment for the use of amphetamines increased (from 7% to 17%). 
• There were no substantial changes to the treatment types received by clients. 
2.2 Agencies 
In 2013–14, a total of 795 publicly funded AOD treatment agencies provided data about 
services for clients seeking treatment services and support, an increase of 19% over the  
5-year period from 2009–10. Over half (56%) of treatment agencies were non-government, 
and these agencies provided almost two-thirds (63%) of closed treatment episodes. 
Nationally, just over half (57%) of treatment agencies were located in Major cities and almost 
one-quarter (23%) in Inner regional areas. Relatively few agencies were in Remote or Very 
remote areas (7%) (tables SA.1–SA.3). 
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2.3 Clients 
In 2013–14, 118,741 clients were estimated to have received treatment from publicly funded 
AOD treatment agencies across Australia. This equates to a rate of 509 clients per 100,000 
people, or about 1 in 200 people in the general population. These clients received over 
180,000 treatment episodes (Table 2.1) (see Appendix B for details of the imputation strategy 
used to estimate client numbers). Between 2012–13 and 2013–14, the number of estimated 
clients rose from 110,427 to 118,741, an 8% increase. 
Clients can receive treatment for their own or someone else’s drug use (see the Glossary for 
further details). In 2013–14, around 113,000 clients received treatment for their own drug use, 
and about 7,000 received support in relation to someone else’s drug use (Table 2.1). A small 
proportion (1.1%) of clients received treatment for both their own drug use and someone 
else’s drug use in 2013–14.  
Table 2.1: Estimated clients(a), episodes and rates, by client type and state and territory, 2013–14 
 
NSW Vic Qld WA SA Tas ACT NT Aust 
Own drug use 
Number of episodes 40,824 52,261 35,127 19,456 12,979 2,649 4,545 3,917 171,758 
Number of clients 25,545 27,427 28,394 14,430 9,282 2,271 3,231 2,599 112,573 
Episodes per client 1.6 1.9 1.2 1.3 1.4 1.2 1.4 1.5 1.5 
Rate of episodes(b) (per 100,000 population) 547 902 749 763 774 515 1,183 1,615 737 
Rate of clients(b) (per 100,000 population) 342 474 605 566 553 442 841 1,071 483 
 Other’s drug use 
Number of episodes 1,582 4,131 966 1,411 106 192 107 460 8,955 
Number of clients 954 3,208 909 1,363 89 191 106 410 7,174 
Episodes per client 1.7 1.3 1.1 1.0 1.2 1.0 1.0 1.1 1.2 
Rate of episodes(b) (per 100,000 population) 21 71 21 55 6 37 28 190 38 
Rate of clients(b) (per 100,000 population) 13 55 19 53 5 37 28 169 31 
 All clients 
Number of episodes 42,406 56,392 36,093 20,867 13,085 2,841 4,652 4,377 180,713 
Number of clients 26,402 29,877 29,207 15,760 9,365 2,444 3,332 2,963 118,741 
Episodes per client 1.6 1.9 1.2 1.3 1.4 1.2 1.4 1.5 1.5 
Rate of episodes(b) (per 100,000 population) 568 974 769 818 780 553 1,211 1,804 775 
Rate of clients(b) (per 100,000 population) 354 516 623 618 558 476 867 1,222 509 
(a) Client numbers presented are the imputed total (estimated from data with and without a valid SLK). Refer to Appendix B for further details. 
(b) Crude rate is based on the preliminary Australian estimated resident population as at 31 December 2013. 
Sources: Tables SC.21 and SC.27. 
Of all clients receiving treatment, 2 in 3 (67%) were male and around 1 in 7 (14%) were 
Aboriginal and Torres Strait Islander (from here on referred to as ‘Indigenous Australians’). 
These proportions were similar for clients receiving treatment for their own drug use, 
however clients receiving support for someone else’s drug use were more likely to be female 
(64%) and less likely to be Indigenous (8%) (tables SC.1 and SC.3).  
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Note: Client numbers presented are imputed (estimated from data with and without a valid SLK). Proportions presented are not imputed (based on 
data with a valid SLK). 
Sources: Tables SC.1–SC.3, SC.21–SC.23 and SE.7. 
Figure 2.1: Estimated clients, key facts, 2013–14 
Clients receiving treatment for their own drug use tended to be younger, on average, than 
clients receiving support for someone else’s drug use. In 2013–14, clients aged 20–39 
represented over half (56%) of clients receiving treatment for their own drug use, but only 
about one-third (29%) of clients receiving support for someone else’s drug use. Clients aged 
40 and over comprised nearly one-third (31%) of clients receiving treatment for their own 
drug use, compared with over half (57%) of clients receiving support for someone else’s drug 
use (Table SC.2). 
Over the 5 years to 2013–14, the proportion of treatment episodes for clients who were aged 
20–29 fell from 29% to 27%, while the proportion for those aged 40 and over rose from 30% to 
33%. The proportion of episodes for those aged 10–19 and 30–39 has remained stable over 
time. This suggests that there is an ageing cohort of people in AOD treatment (Table SE.5). 
Despite only comprising 2.7% of the Australian population aged 10 and over, 14% of all 
clients were Indigenous Australians in 2013–14 (ABS 2014). This varied by client type—about 
1 in 7 (14%) clients receiving treatment for their own drug use were Indigenous Australians, 
while 8% of clients receiving support for someone else’s drug use were Indigenous 
Australians (Table SC.3). 
The majority (86%) of treatment episodes were for clients who were born in Australia. This 
percentage is higher than that found in the general population (72%) (ABS 2015). Clients 
born in countries other than Australia represented only a small proportion of all clients, with 
the United Kingdom and New Zealand being the next most common countries of birth (2% 
and 3% respectively) (Table SE.7). Comparatively, in 2013–14, 5.2% of the Australian 
population were born in the United Kingdom and 2.6% in New Zealand (ABS 2015). English 
118,741 clients
74% received 1 
treatment episode
86% received treatment 
at 1 agency
74% aged between 
20-49 years




86% born in 
Australia
95% seeking 
treatment for own 
drug use
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was the most frequently reported preferred language (96% of treatment episodes for clients) 
(Table SE.8).  
Australia has an ageing population and therefore an anticipated increase in absolute 
numbers of older Australians with AOD issues (Dowling et al. 2008). Further, Gossop (2008) 
estimates that, internationally, the number of older people needing treatment for AOD issues 
will double between 2000 and 2020. While the demographic profile of clients receiving 
treatment and support from publicly funded AOD services has changed little since 2003–04, 
in more recent years the age profile of people receiving treatment suggest there is an ageing 
cohort of AOD clients. 
In 2013–14, clients seeking treatment for their own drug use received an average of 1.5 
treatment episodes (Table 2.1). The main drugs that led clients to seek treatment were 
alcohol, cannabis, amphetamines and heroin. This was consistent for both Indigenous and 
non-Indigenous clients.  
Further information on clients is provided in Chapters 4 and 5. 
2.4 Drugs of concern and treatment provided 
In 2013–14, AOD treatment services provided a total of 180,713 closed treatment episodes 
(see Box 2.1), an increase of 24% since 2009–10 (from 145,630 to 180,713 episodes). The 
majority (95%) of closed treatment episodes provided in 2013–14 were for clients receiving 
treatment for their own drug use (SE.1).  
In 2013–14, the most common principal drugs of concern (the primary drug leading someone 
to seek treatment, see Box 2.1) were alcohol (40% of episodes), cannabis (24%), 
amphetamines (17%) and heroin (7%). Since 2009–10, the proportion of episodes where 
alcohol was the principal drug of concern has decreased (from 48% to 40%), while the 
proportion of episodes for amphetamines increased (from 7% to 17%) (Table SE.9). 
In more than half (54%) of closed treatment episodes, the client also reported additional 
drugs of concern. Almost one-third (29%) had 1 additional drug of concern, 13% had 2 drugs, 
and 2% had 5. Nicotine and cannabis were the most common additional drugs of concern 
(Table SD.6). 
Since 2003–04, the proportion of closed treatment episodes for each main treatment type (see 
Box 2.1) remained relatively stable. Counselling continues to be the most common main 
treatment type provided (comprising about 2 in 5 episodes since 2003–04), however, since 
2012–13, assessment only has replaced withdrawal management as the next most common 
(Table ST.4). 
In 2013–14, the majority of treatment episodes for clients receiving treatment for their own 
drug use were provided by non-residential treatment facilities, such as community health 
centres. Episodes provided for the 4 most common principal drugs of concern (alcohol, 
cannabis, amphetamines and heroin) were most likely to be provided by non-residential 
treatment facilities (67% of episodes), followed by residential treatment facilities (where 
clients reside in a facility that is not their home or usual place of residence) (16%) and 
outreach settings (10%) (Table SD.12). 
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Box 2.1: Key terminology 
Closed treatment episode 
A treatment episode is considered closed where any of the following occurs: treatment is 
completed or has ceased, there has been no contact between the client and treatment 
provider for 3 months, there is a change in the main treatment type, principal drug of 
concern or delivery setting. 
Treatment episodes are excluded from the AODTS NMDS if they: are not closed in the 
relevant financial year, are for clients who are receiving pharmacotherapy and not receiving 
any other form of treatment that falls within the scope of the collection, include only 
activities relating to needle and syringe exchange, or are for a client aged under 10. 
Drugs of concern 
Principal drug of concern is the main substance that the client stated led them to seek 
treatment from the AOD treatment agency. In this report, only clients seeking treatment for 
their own substance use are included in analyses of principal drug of concern. It is assumed 
that only substance users themselves can accurately report principal drug of concern, 
therefore these data are not collected from those who seek support for someone else’s drug 
use. 
Additional drugs of concern refer to any other drugs the client reports using in addition to the 
principal drug of concern. Clients can nominate up to 5 additional drugs of concern. 
All drugs of concern refer to all drugs reported by clients, including the principal drug of 
concern and any additional drugs of concern. 
Reasons for cessation 
The reasons for a client ceasing to receive a treatment episode from an AOD treatment 
service include: 
• Expected cessation: episodes where the treatment was completed, or where the client 
ceased to participate at expiation or by mutual agreement. 
• Unexpected cessation: episodes where the client ceased to participate against advice, 
without notice or due to non-compliance. 
• Administrative cessation: episodes that ended due to a change in main treatment type, 
delivery setting or principal drug of concern, or where the client was transferred to 
another service provider. 
Treatment types 
Treatment type refers to the type of activity used to treat the client’s alcohol or other drug 
problem. Rehabilitation, withdrawal management (detoxification) and pharmacotherapy 
are not available for clients seeking support for someone else’s drug use.  
Main treatment type is the principal activity that is determined at assessment by the 
treatment provider necessary for the completion of the treatment plan for the client’s 
alcohol or other drug problem for their principal drug of concern. One main treatment type 
is reported for each treatment episode. Assessment only, support and case management 
only, and information and education only can only be reported as main treatment types. 
Other treatment types refer to other treatment types provided to the client, in addition to their 
main treatment type. Up to 4 additional treatment types can be reported. Note that Victoria 
and Western Australia do not supply data on additional treatment types. In these 
jurisdictions, each type of treatment (main or additional) results in a separate episode. 
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In 2013–14, 4 in 5 (79%) closed treatment episodes ended within 3 months, under one-quarter 
(24%) ended within 1 day, almost 3 in 10 (30%) between 2 days and 1 month, and one-
quarter of episodes (25%) between 1 and 3 months. Only 7% of closed treatment episodes 
lasted 6 months or longer. Nationally, the median duration of closed treatment episodes in 
2013–14 was just over 3 weeks (24 days) (tables SE.18–19). 
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3 Agencies 
The Australian Government and state and territory governments fund both government and 
non-government organisations to provide a range of AOD treatment services (see Glossary). 
Services are delivered in residential and non-residential settings and include treatment such 
as detoxification, rehabilitation, counselling, and pharmacotherapy. 
The AODTS NMDS contains information on a subset of publicly funded AOD treatment 
services (see section 1.4 for details of agencies that are excluded).  
3.1 Key facts 
In 2013–14: 
• A total of 795 publicly funded agencies provided data about services for clients seeking 
treatment and support. 
• Over half (56%) of agencies were non-government. 
• Just over half (57%) of agencies were located in Major cities. 
Over the 5-year period to 2013–14: 
• The number of publicly funded agencies providing data about services for clients 
seeking treatment and support increased by 19%. 
3.2 Number of agencies 
In 2013–14, 795 publicly funded AOD treatment agencies reported to the AODTS NMDS, an 
increase of 9.4 percentage points since 2012–13 in the number of agencies nationally. This 
represents nearly all (99.5%) agencies covered by the AODTS NMDS. The number of 
agencies per state and territory ranged from 15 in the Australian Capital Territory to 292 in 
New South Wales (Table SA.1). 
Over the 5-year period to 2013–14, there has been a 19% increase in the number of reporting 
agencies (from 670 to 795). This increase has largely been driven by increases in reporting 
agencies in New South Wales (from 258 to 292), Queensland (from 118 to 141), Western 
Australia (from 52 to 80) and South Australia (from 59 to 93) (Table SA.1). 
Several factors can contribute to changes in the number of agencies reporting between years, 
including changes in the actual numbers of agencies and changes in the mode of data 
collection. For example, agencies may move from collecting data at an 
administrative/management level to a service outlet level (see the Data quality statement 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/606485> for further 
information). 
3.3 Service sector 
Nationally, over half (56%) of AOD treatment agencies were non-government, and these 
agencies provided almost two-thirds (63%) of closed treatment episodes (Figure 3.1). The 
proportion of non-government agencies has increased slightly since 2003–04 (from 52% to 
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56%), while the proportion of government agencies has decreased slightly (from 48% to 44%) 
(Table SA.2). 
In New South Wales (74%) and South Australia (53%) the majority were government 
agencies. In the remaining states and territories most were non-government agencies, 
ranging from 57% in Queensland to 100% in Victoria (Figure 3.1). 
 
Source: Table SA.2. 
Figure 3.1: Publicly funded AOD treatment agencies by service sector, by state and territory,  
2013–14 
3.4 Remoteness 
Nationally in 2013–14, over half (57%) of treatment agencies were located in Major cities and 
nearly one-quarter (23%) in Inner regional areas. Relatively few agencies were in Remote or 
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4 Drugs of concern 
People may seek AOD treatment services due to problematic use of one or more drugs. For 
most people, however, there is one drug that is of most concern for them, and therefore the 
focus of the treatment they receive. This is referred to as their principal drug of concern. 
Clients can also report other drugs of concern (referred to as additional drugs of concern). 
Information on clients and treatment agencies are included in the AODTS NMDS when a 
treatment episode provided to a client is closed (see Box 2.1 for more information).  
While there are many different drugs people receive treatment for, the most common 
principal drugs of concern—alcohol, cannabis, heroin and amphetamines—have accounted 
for the large majority of services over time (Figure 4.1). Due to this consistent trend, the focus 
of this chapter will be on these four principal drugs of concern for clients in treatment. 
(Where a person receives treatment for someone else’s drug use, the principal drug of 
concern for that person is not collected. Thus, no information is presented in this chapter on 
support received for someone else’s drug use.) 
 
Source: Table SD.2.  
Figure 4.1: Closed episodes provided for own drug use, by selected principal drug of concern,  
2003–04 to 2013–14  
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4.1 Key facts 
In 2013–14: 
• Nationally, alcohol was the most common principal drug of concern, accounting for 
40% of episodes (Figure 4.2). 
• Cannabis was the most common principal drug of concern for clients aged 10–29, while 
alcohol was the most common principal drug of concern for clients aged 30 and over. 
• After alcohol, cannabis (24%), amphetamines (17%) and heroin (7%) were the next 
most common principal drugs of concern (Figure 4.2).  
• Alcohol was the most common principal drug of concern in all remoteness areas—
highest in Very remote areas (71%) and lowest in Major cities (38%). 
• For the top four principal drugs of concern, most clients received treatment in a 
residential facility—alcohol (63% of episodes for alcohol), cannabis (71%), 
amphetamines (70%) and heroin (65%). 
• Clients whose principal drug of concern was heroin or amphetamines generally spent 
longer in treatment; the median duration of episodes was 29 days compared to 23 days 
for all treatment episodes. 
Over the 5-year period to 2013–14: 
• The top four principal drugs of concern have remained consistent. However, between 
2003–04 and 2013–14 amphetamines and heroin have replaced each other as the third 
and fourth most common principal drugs of concern several times. 
• The trend in the top four principal drugs of concern has been consistent for both 
Indigenous and non-Indigenous clients. 
• The number of episodes for clients injecting and smoking/inhaling amphetamines has 
increased, with more than 6 times as many clients smoking and inhaling in 2013–14 
than in 2009–10. 
 
  
 16 Alcohol and other drug treatment services in Australia 2013–14 
Principal drug
69,479 (40%)
No additional drugs of concern
37,911 (55% of episodes with alcohol as principal)








No additional drugs of concern
17,239 (43%)









No additional drugs of concern
10,791 (37%)










No additional drugs of concern
941 (36%)






















No additional drugs of concern
4,406 (37%)
















No additional drugs of concern
1,306 (46%)







Note: Totals may not add due to rounding. 
Sources: Tables SD.6, SD.7 and SD.9.  
Figure 4.2: Closed episodes for own drug use, by principal drug of concern and additional drugs of 
concern, 2013–14  
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Nationally, alcohol was the most common principal drug of concern, accounting for more 
than a third (39%) of clients, followed by cannabis (26% of clients) and amphetamines (16%) 
(Table SC.4).  
The proportion of clients receiving treatment where alcohol was the principal drug of 
concern increased substantially with age. Alcohol was the principal drug of concern for one 
in five (19%) of clients aged 10–19, but was more common in the older age groups—66% of 
those aged 50–59 and 81% of clients aged 60 and over (Figure 4.3). For clients receiving 
treatment for cannabis the opposite was true, with the proportion of clients decreasing with 
age. Clients aged 10–29 were most likely to be receiving treatment for cannabis use, with 
cannabis the principal drug of concern for more than half (60%) of clients aged 10–19, 
compared with 11% of those aged 50–59 and only 4% of clients aged 60 and over.  
 
Note: Based on client records with a valid SLK. 
Source: Table SC.5. 
Figure 4.3: Principal drugs of concern for clients by age group, 2013–14 
Clients receiving treatment where amphetamines and heroin were the principal drugs of 
concern were most likely to be aged 20–49. Amphetamines were most likely to be the 
principal drug of concern for clients aged 20–39 (ranging from 20 to 23% of clients), whereas 
only 9% of those aged 10–19 and 5% of clients aged 50–59 were receiving treatment. Heroin 
was most common among clients aged 30–49 (ranging from 7 to 10%), compared with only 
1% of clients aged 10–19 and 5% of clients aged 50–59. 
4.2 Alcohol 
Alcohol is a central nervous system depressant that inhibits brain functions, dampens the 
motor and sensory centres and makes judgment, coordination and balance more difficult 
(NDARC 2010). According to the 2009 Australian guidelines to reduce health risks from drinking 
alcohol (NHMRC 2009), people who drink more than 2 standard drinks per day on average 
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who drink more than 4 standard drinks on a single occasion are at risk of harm on that 
occasion (AIHW 2014). 
Results from the 2013 NDSHS (AIHW 2014) showed: 
• About 78% of Australians aged 14 and over drank alcohol in the previous 12 months. 
• A significant proportion of the Australian population drank at risky levels—1 in 5 (17%) 
aged 14 years and over drank at a level that put them at risk of alcohol-related harm over 
their lifetime, while 1 in 4 (26%) drank at levels that put them at risk of harm from a 
single drinking occasion at least once in the previous 12 months. 
• Males are more likely than females to drink at levels that place them at risk of harm over 
their lifetime and on a single occasion. 
In 2013–14, alcohol was a drug of concern (principal or additional) in 57% of closed episodes, 
and the most common principal drug of concern in 40% (39% of clients) (Figure 4.2 and Table 
SC.4). This was consistent for both Indigenous and non-Indigenous clients, however the 
proportion of episodes where alcohol was the most common principal drug of concern was 
higher for Indigenous Australians—46% compared with 38% for non-Indigenous clients 
(Table SC.6). In 45% of episodes where alcohol was the principal drug of concern, the client 
reported additional drugs of concern. These were most commonly cannabis (33%) or nicotine 
(31%) (Figure 4.2). 
For those clients who received episodes of treatment during both 2012–13 and 2013–14, 
alcohol was the main drug that led them to seek treatment in 39% of episodes (Table SC.29). 
Over the 5 years to 2013–14, the proportion of closed episodes where alcohol was the 
principal drug of concern decreased from 48% to 40% (Table SD.2). 
Client demographics 
In 2013–14, where alcohol was the principal drug of concern, more than two-thirds of clients 
were male (68%) and just under one-sixth were Indigenous Australians (17%) (tables SC.4–6). 
Clients with alcohol as their principal drug of concern were most likely to be aged 30–39 or 
40–49 (both 26% of clients), followed by 20–29 (20%) and 50–59 (14%). Indigenous clients 
who had a principal drug of concern of alcohol tended to be younger, with over half (56%) 
aged 20–39 (Figure 4.4). 
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Note: Based on client records with a valid SLK. 
Source: AIHW analysis of the AODTS NMDS. 
Figure 4.4: Number of clients with alcohol as a principal drug of concern, by age and Indigenous 
status, 2013–14 
Treatment 
In 2013–14, where alcohol was the principal drug of concern, the most common source of 
referral for treatment episodes was self/family (47%), followed by a health service (31%) 
(Table SD.21). 
The most common main treatment type was counselling (45%), followed by withdrawal 
management (18%) and assessment only (15%)—this was consistent across all age groups 
(Table SD.25).  
Over the 5 years from 2009–10, counselling, withdrawal management and assessment only 
have remained the most common main treatment types for episodes where alcohol was the 
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Source: Table SD.26. 
Figure 4.5: Closed episodes with alcohol as the principal drug of concern by the top 4 treatment 
types received, 2009–10 to 2013–14 
Alcohol-related treatment episodes were most likely to take place in a non-residential 
treatment facility (63%), with one-fifth (19%) occurring in a residential treatment facility. 
Most (91%) episodes where counselling was the main treatment type took place in a non-
residential treatment facility, while episodes with a main treatment type of withdrawal 
management were most likely to take place in a residential treatment facility (62%) (Table 
SD.28). 
About two-thirds (64%) of closed episodes where alcohol was the principal drug of concern 
ended with an expected cessation, while 21% ended due to an unexpected cessation (that is, 
the client ceased to participate against advice, without notice or due to non-compliance). 
Expected cessations were most common where the referral source was diversion (81%) 
(Table SD.29). 
4.3 Cannabis 
Cannabis (‘marijuana’ or ‘gunja’) is derived from the cannabis plant (usually Cannabis sativa) 
and is used in whole plant (typically the flowering heads), resin or oil forms. Cannabis has a 
range of stimulant, depressant and hallucinogenic effects. The risks associated with long-
term or regular use of cannabis include: addiction, damage to lungs and lung functioning, 
effects on memory and learning, and psychosis and other mental health conditions. Cannabis 
withdrawal is now listed as a discrete syndrome in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V) (NCPIC 2011). According to the 2013 NDSHS (AIHW 2014), 1 in 3 
Australians aged 14 and over have used cannabis at some point in their lifetime, while 1 in 
10 have used it in the previous 12 months. 
In 2013–14, cannabis was a drug of concern (principal or additional) in 44% of episodes, and 
was the second most common principal drug of concern (24% of closed treatment episodes 
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and 26% of Indigenous clients and 27% of non-Indigenous clients) (Figure 4.2 and Table 
SC.6). In more than half (57%) of episodes with cannabis as the principal drug of concern, the 
client reported additional drugs of concern. This was most commonly alcohol (34%), nicotine 
(25%) or amphetamines (20%) (Figure 4.2). 
For those clients who received episodes of treatment during both 2012–13 and 2013–14, 
cannabis was the main drug that led them to seek treatment in 26% of episodes (Table SC.29). 
The proportion of episodes where cannabis was the principal drug of concern has remained 
relatively stable over the 5 years to 2013–14 (Table SD.2). The small increase seen between 
2011–12 and 2012–13 was in part due to the inclusion of new data in 2012–13 from the Drug 
Diversion Assessment Program in South Australia. 
Client demographics 
In 2013–14, where cannabis was the principal drug of concern, nearly three-quarters of 
clients were males (73%), and around 1 in 7 were Indigenous Australians (14%). Cannabis 
was most likely to be the principal drug among younger age groups—two-thirds (66%) of 
clients aged 10–29 had a principal drug of concern of cannabis (tables SC.4–6). This pattern 
was similar for both Indigenous and non-Indigenous clients (Figure 4.6). 
 
Note: Based on client records with a valid SLK. 
Source: AIHW analysis of the AODTS NMDS. 
Figure 4.6: Number of clients with cannabis as a principal drug of concern, by age and Indigenous 
status, 2013–14 
Treatment 
The most common source of referral for treatment episodes where cannabis was the 
principal drug of concern was diversion (that is, referred from the criminal justice system 
into AOD treatment for drug or drug-related offences) (33%) (Table SD.37). Of the top four 
principal drugs of concern, cannabis was the only drug where diversion was the most 
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‘diversion’ as the most common source of referral (70% and 42% respectively). Ecstasy was 
reported as the principal drug in just 1% of episodes and nicotine in just 2% of episodes. 
 
Source: Table SE.10. 
Figure 4.7: Closed episodes provided to clients by selected principal drug of concern and diversion 
client type, 2013–14 
Counselling was the most common main treatment type (40%) where cannabis was the 
principal drug of concern, followed by information and education only (21%) (Table SD.41). 
Treatment episodes where cannabis was the principal drug of concern were most likely to 
take place in a non-residential treatment facility (71%). Most (91%) episodes where 
counselling was the main treatment type took place in a non-residential treatment facility 
(Table SD.44). 
Over the 5 years from 2009–10, in episodes where cannabis was the principal drug, the 
proportion of episodes with a main treatment type of counselling increased from 37% to 
40%, with a high of 43% in 2011–12 (Figure 4.8). 
More than half (58%) of the episodes with cannabis as the principal drug lasted less than 1 
month (34% ended within 1 day) (Table SE.22). The median duration of episodes with 
cannabis as the principal drug of concern was just over 2 weeks (16 days) (Table SD.47). 
Episodes with support and case management only as the main treatment type had a median 
duration of more than 8 weeks (57 days), compared with 1 week (8 days) for withdrawal 
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Source: Table SD.42. 
Figure 4.8: Closed episodes with cannabis as the principal drug of concern by the top 5 treatment 
types received, 2009–10 to 2013–14 
Seven in 10 (70%) closed episodes where cannabis was the principal drug of concern ended 
with an expected cessation, and, expected cessations were most common for episodes where 
the client was diverted from the criminal justice system (43%). Around 1 in 5 (19%) episodes 
ended due to an unexpected cessation (Table SD.45). 
4.4 Amphetamines 
Amphetamines stimulate the central nervous system and can result in euphoria, increased 
energy, decreased appetite, paranoia and increased blood pressure (ADCA 2013). Long-term 
effects include: high blood pressure, extreme mood swings, depression, anxiety, psychosis 
and seizures. There is no approved pharmacotherapy for the management of amphetamine 
withdrawal or replacement therapy (Lee et al. 2007). According to the 2013 NDSHS (AIHW 
2014), 1 in 14 Australians aged 14 and over have used meth/amphetamines for non-medical 
purposes at some point in their lifetime, while 1 in 50 have used them in the previous 12 
months. 
In 2013–14, amphetamines were a drug of concern (principal or additional) in 30% of closed 
treatment episodes, and were the third most common principal drug of concern (17% of all 
episodes and 16% of clients) (Figure 4.2 and Table SC.4). This was consistent for both 
Indigenous and non-Indigenous clients, however, the proportion of episodes where 
amphetamines were the most common principal drug of concern was higher for non-
Indigenous clients—16% compared with 13% for Indigenous Australians (Table SC.6). In just 
under two-thirds (63%) of episodes with a principal drug of concern of amphetamines, the 
client reported additional drugs of concern. These were most commonly cannabis (31%), 
alcohol (22%) and nicotine (20%) (Figure 4.2). 
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For those clients who received episodes of treatment during both 2012–13 and 2013–14, 
amphetamines were the main drug that led them to seek treatment in 16% of episodes (Table 
SC.29). 
In 2013–14, injecting was the most common usual method of use (44% of episodes), followed 
by smoking/inhaling (41%) (Table SD.55). 
Over the 5 years to 2013–14, the proportion of episodes where amphetamines were the 
principal drug of concern has increased (from 7% to 17%) (Table SD.2). According to the 2013 
NDSHS (AIHW 2014), the proportion of the adult population using methamphetamine in the 
previous 12 months has remained fairly stable (declining only slightly from 2.4% to 2.1% 
between 2007–2013). However, among recent methamphetamine users there has been a 
change in the main form used—a significant increase in the use of crystal methamphetamine 
or ‘ice’ (from 27% to 50% over the same time period). 
Client demographics 
In 2013–14, more than two-thirds of clients receiving treatment for a principal drug of 
amphetamines were male (70%), and just under one-sixth of clients were Indigenous 
Australians (11%). Clients with a principal drug of concern of amphetamines were most 
likely to be aged 20–39 (74%), followed by those aged 40–49 (15%) and 10–19 (8%) (tables 
SC.4–6). The age profile was similar for Indigenous and non-Indigenous clients (Figure 4.9). 
 
Note: Based on client records with a valid SL. 
Source: AIHW analysis of the AODTS NMDS. 
Figure 4.9: Number of clients with amphetamines as a principal drug of concern, by age and 
Indigenous status, 2013–14 
Treatment 
The most common source of referral for treatment episodes where amphetamines were the 
principal drug of concern was self/family (43%), followed by diversion and health services 
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In 2013–14, the most common main treatment type for episodes where amphetamines was 
the principal drug of concern was counselling (45%), followed by assessment only (19%) and 
withdrawal management (11%) (Table SD.57). Treatment was most likely to take place in a 
non-residential treatment facility (70%) (Table SD.60). 
Over the 5 years from 2009–10, where amphetamines were the principal drug, the proportion 
of episodes where counselling was the main treatment type declined (from 51% to 45%) 
(Figure 4.10).  
 
Source: Table SD.58. 
Figure 4.10: Closed episodes with amphetamines as the principal drug of concern by the top 4 
treatment types received, 2009–10 to 2013–14 
Just over half (51%) of episodes where amphetamines were the principal drug of concern 
lasted less than 1 month (17% ended within 1 day and were mostly for the main treatment 
type of information and education only) (Table SE.22). The median duration of episodes was 
just over 4 weeks (29 days). Episode duration varied depending on the main treatment 
type—episodes with a main treatment type of counselling had a median duration of 8 weeks 
(56 days), while episodes with withdrawal management ended within 1 week (7 days) and 
information and education only lasted a median duration of 1 day (Table SD.63). 
Three-fifths (62%) of closed episodes where amphetamines were the principal drug of 
concern ended with an expected cessation, with expected cessations most common for 
episodes where diversion was the referral source (78%). One-quarter (25%) of episodes 
ended with an unexpected cessation (Table SD.61). 
Over the 5 years to 2013–14, the number of episodes for clients injecting and 
smoking/inhaling amphetamines increased. In 2013–14, clients were 6 times as likely to 
smoke/inhale amphetamines as they were in 2009–10 (Figure 4.11).  
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Note: 'Other' includes 'Ingests', 'Sniffs' and 'Other'. 
Source: Table SD.55. 
Figure 4.11: Closed episodes provided for own drug use with a principal drug of concern of 
amphetamines, by method of use, 2003–04 to 2013–14 
4.5 Heroin 
Heroin is one of the opioid drugs, which are strong pain killers with addictive properties. 
Short-term side effects of use include pain relief and feelings of euphoria and wellbeing, 
while long-term effects can include lowered sex drive and infertility (for women), along with 
risk of overdose, coma and death (ADCA 2013). Heroin users seeking treatment can 
undertake a withdrawal program (also called detoxification), an abstinence-based treatment 
(for example, residential rehabilitation in a therapeutic community), or attend an opioid 
maintenance substitution program (O’Brien 2004). Results from the 2013 NDSHS (AIHW 
2014) showed: 
• In 2013, 1.2% of people in Australia aged 14 and over had used heroin in their lifetime 
and 0.1% had used it in the previous 12 months. 
• There was a significant decline in the proportion of people using heroin between 2010 
and 2013. 
In 2013–14, heroin was a drug of concern (principal or additional) in 10% of closed treatment 
episodes, and was the fourth most common principal drug of concern in 7% of episodes  
(6% of clients) (Figure 4.2 and Table SC.4). This was consistent for both Indigenous and non-
Indigenous clients, however, the proportion of episodes where heroin was the most common 
principal drug of concern was higher for non-Indigenous clients—6% compared with 4% for 
Indigenous Australians (Table SC.6). In just under two-thirds (63%) of episodes with heroin 
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as the principal drug of concern, the client reported additional drugs of concern. These were 
most commonly cannabis (21%) and amphetamines (19%) (Figure 4.2). 
Injecting was the most common method of use in most episodes where the principal drug of 
concern was heroin (83% of episodes) (Table SD.87). In 3 in 5 (59%) episodes, the client 
reported they had injected drugs in the previous 3 months, while 16% reported they last 
injected 3–12 months ago (injecting status was not reported for 8% of episodes) (Table 
SD.88). 
For those clients who received episodes of treatment during both 2012–13 and 2013–14, 
heroin was the principal drug of concern in 6.0% of episodes (Table SC.29). 
Over the 5 years from 2009–10, the proportion of episodes where heroin was the principal 
drug of concern decreased steadily (from 10% to 7%) (Table SD.2). 
Client demographics 
Where heroin was the principal drug of concern, 69% of clients were male and 10% were 
Indigenous Australians. Clients with heroin as their principal drug of concern were most 
likely to be aged 30–39 (46%), followed by those aged 20–29 and 40–49 (both 22%) (tables 
SC.4–6). This pattern was similar for Indigenous and non-Indigenous clients (Figure 4.12). 
 
Note: Based on client records with a valid SLK. 
Source: AIHW analysis of the AODTS NMDS. 
Figure 4.12: Number of clients with heroin as a principal drug of concern, by age and Indigenous 
status, 2013–14 
Treatment 
The most common source of referral for treatment episodes where heroin was the principal 
drug of concern was self/family (50%), followed by a health service (20%) and diversion 
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The most common main treatment types were counselling (35%), withdrawal management 
(18%) and assessment only (16%) (Table SD.89). Note this collection does not systematically 
cover replacement therapies. Treatment episodes with heroin as the principal drug of 
concern were most likely to take place in a non-residential treatment facility (65%) (Table 
SD.92). 
Over the 5 years to 2013–14, the proportion of episodes with withdrawal management as the 
main treatment type for the principal drug of concern of heroin decreased (from 26% to 18%) 
(Figure 4.13). 
 
Source: Table SD.90. 
Figure 4.13: Closed episodes with heroin as the principal drug of concern by the top 4 treatment 
types received, 2009–10 to 2013–14 
Half (50%) of episodes where heroin was the principal drug of concern lasted less than 1 
month (20% ended within 1 day and were mostly for the main treatment types of 
information and education only and assessment only) (Table SE.22). The median duration of 
episodes with heroin as the principal drug of concern was just over 4 weeks (29 days). 
Episodes with counselling as the main treatment type had a median duration of 10 weeks (70 
days) and support and case management only had a median duration of more than 9 weeks 
(66 days). While episodes with a main treatment type of withdrawal management had a 
median duration of around one week (6 days) and 1 day for both information and education 
only and assessment only (Table SD.95). 
More than half (57%) of closed episodes with heroin as the principal drug of concern ended 
with an expected cessation, and expected cessations were most common where the main 
treatment type was information and education only (87%) as this treatment type is usually 
completed within a day (Table SD.93). 
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4.6 Selected other drugs 
A number of other drugs make up a smaller proportion of overall treatment services. These 
drugs may be less prominent in treatment services as they are less common or users are less 
likely to seek treatment. Information on the following drugs is presented in this section due 
to the size of the population using the drug and/or harms associated with use of that drug. 
Nicotine 
Nicotine is the stimulant drug in tobacco smoke. It is highly addictive and causes 
dependency (ADCA 2013). Almost 8% of Australia’s burden of disease was attributable to 
tobacco smoking in 2003 (Vos et al. 2007). The health effects of smoking include premature 
death and tobacco-related illnesses such as cancer, chronic obstructive pulmonary disease 
and heart disease. According to the 2013 NDSHS (AIHW 2014) almost 1 in 6 Australians 
were current smokers and 1 in 8 were daily smokers. 
Most of the population access various forms of treatment for nicotine addiction through their 
local general practitioner, pharmacy, helplines or web services. Smoking cessation treatment 
and support services include brief intervention by trained health professionals, individual or 
group counselling, telephone counselling, and pharmacotherapies including nicotine 
replacement therapies and non-nicotine products. 
Nicotine was a principal drug of concern in just 2% of episodes. However, it was an 
additional drug of concern in a further 22% of episodes (Figure 4.2). The proportion of 
episodes with nicotine as the principal drug has remained stable at 1–2% since 2003–04 
(Table SD.2). Possible reasons for the low proportion of episodes in which nicotine was the 
principal drug include the wide availability of support and treatment for nicotine use in the 
community, and that people tend to view AOD treatment services as most appropriate for 
drug use that is beyond the expertise of general practitioners. 
Client demographics 
Where nicotine was a principal drug of concern, 63% of clients were male and 11% were 
Indigenous Australians. Clients with nicotine as a principal drug of concern were most likely 
to be aged 10–29 (49%). Only 6% of clients were aged 60 or over (tables SC.4–6). Nicotine was 
more likely to be an additional drug of concern rather than the principal drug for all age 
groups—of all episodes where nicotine was a drug of concern, it was an additional drug of 
concern in 93% of episodes (Table SD.66). 
Treatment 
The most common source of referral for treatment episodes where nicotine was the principal 
drug of concern was a police or court diversion program (42%), followed by self/family 
(25%) (Table SD.69).  
Counselling (32%), information and education only (26%) and assessment only (19%) were 
the most common main treatment types (Table SD.73). Treatment episodes where nicotine 
was the principal drug of concern were most likely to take place in a non-residential 
treatment facility (66%) (Table SD.78). 
Just over three-fifths (61%) of episodes with nicotine as the principal drug lasted less than 
1 month (32% ended within 1 day and were mostly for the main treatment type of 
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information and education only) (Table SE.22). The median duration of episodes with 
nicotine as the principal drug of concern was 15 days (Table SD.79). 
More than three-quarters (82%) of episodes with nicotine as the principal drug of concern 
ended with an expected cessation, while one in ten (10%) ended due to an unexpected 
cessation. Expected cessations were most common where the main treatment type was 
information and education only (31%) (Table SD.78). 
Ecstasy 
Ecstasy is the popular street name for a range of drugs said to contain the substance 
3, 4-methylenedioxymethamphetamine (MDMA)—an entactogenic stimulant with 
hallucinogenic properties. Ecstasy is usually sold in tablet or pill form, but is sometimes 
found in capsule or powder form. The short-term effects of ecstasy include euphoria, feelings 
of wellbeing and closeness to others and increased energy. Harms include psychosis, heart 
attack and stroke. Little is known about the long-term effects of ecstasy use, but there is some 
research linking regular and heavy use of ecstasy to memory problems and depression 
(ADCA 2013). According to the NDSHS (AIHW 2014), 2% of Australians aged 14 and over 
used ecstasy in the previous 12 months in 2013. 
Ecstasy was a drug of concern (principal or additional) in 3% of closed episodes in 2013–14 
and was the principal drug in less than 1% of episodes (tables SD.114 and SE.9). Counselling 
was the most common main treatment type for episodes where ecstasy was the principal 
drug (42%), followed by information and education only (32%) and assessment only (18%) 
(Table SD.121). 
Benzodiazepines 
Benzodiazepines are depressant drugs—they slow down the activity of the central nervous 
system and the speed of messages going between the brain and the body. Formerly known 
as ‘minor tranquillisers’, benzodiazepines are most commonly prescribed by doctors to 
relieve stress and anxiety and to aid sleep. They are a drug of dependence and are associated 
with fatal and non-fatal overdose among opioid users. Some people use benzodiazepines 
illegally to become intoxicated or to ‘come down’ from the effects of stimulants such as 
amphetamines or cocaine (ADF 2013). 
According to the 2013 NDSHS (AIHW 2014), 4.5% of Australians aged 14 and over had used 
tranquillisers/sleeping pills (including benzodiazepines) for non-medical purposes at some 
stage in their lifetime. 
In 2013–14, benzodiazepines were a drug of concern (principal or other) in 8% of closed 
episodes and the principal drug in 2% of episodes (Figure 4.2). There was no change in the 
proportion of episodes with benzodiazepines as the principal drug in the 10 years from 
2003–04 (Table SD.2). 
In 64% of the episodes with benzodiazepines as the principal drug, the client reported 
additional drugs of concern. These were most commonly alcohol (18%) and cannabis (17%) 
(Figure 4.2). 
Ingestion was the most common usual method of use (88%) in episodes with 
benzodiazepines as the principal drug although they are commonly crushed and injected 
among injecting drug users (Table SD.103). 
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Client demographics 
Where benzodiazepines were the principal drug of concern, half (51%) of clients were male  
and 8% were Indigenous Australians. More than one-third (36%) of clients with 
benzodiazepines as a principal drug of concern were aged 30–39, just under one-quarter 
(24%) were aged 40–49 and nearly one-fifth (19%) were aged 20–29. Only 7% of clients were 
aged 60 or over (tables SC.4–6).  
Benzodiazepines were more likely to be an additional drug of concern rather than the 
principal drug for all age groups—of all episodes where benzodiazepines were a drug of 
concern, it was an additional drug of concern in 80% of episodes (Table SD.98). 
In more than one-third (37%) of closed episodes, the client reported they had never injected a 
drug, while in 1 of 5 episodes (19%), the client reported they had injected drugs in the 
previous 3 months (injecting status was not reported for 20% of episodes) (Table SD.104). 
Treatment 
The most common source of referral for treatment episodes where benzodiazepines were the 
principal drug of concern was self/family (48%), followed by a health service (36%) (Table 
SD.101). 
The most common main treatment type for episodes where benzodiazepines were the 
principal drug of concern was counselling (35%), followed by withdrawal management 
(25%) and assessment only (16%) (Table SD.105). Treatment episodes were most likely to 
take place in a non-residential treatment facility (64% of episodes) or a residential treatment 
facility (18%). Almost all (94%) episodes where counselling was the main treatment type took 
place in a non-residential treatment facility (Table SD.108). 
More than half (55%) of the episodes with benzodiazepines as the principal drug of concern 
lasted less than 1 month (21% ended within 1 day and were mostly for the main treatment 
type of information and education only) (Table SE.22). The median duration of episodes with 
benzodiazepines as the principal drug of concern was 3 weeks (22 days) (Table SD.111). 
Episodes with counselling and support and case management only as the main treatment 
types had a median duration of just over 9 weeks (67 days each), followed by rehabilitation 
episodes which has a median duration of just over 7 weeks (50 days). In comparison, 
benzodiazepine withdrawal management episodes had a median duration of less than 2 
weeks (10 days) and assessment only and information and education only episodes lasted a 
median of 1 day (Table SD.111). 
Three in 5 (62%) episodes with benzodiazepines as the principal drug of concern ended with 
an expected cessation, while 1 in 5 (18%) ended due to an unexpected cessation. Expected 
cessations were more common for episodes where the main treatment type was information 
and education only (84%) or withdrawal management (66%) (Table SD.112). 
Licit opioids 
Licit opioids can be obtained by prescription—for example, morphine, buprenorphine, 
methadone, oxycodone, fentanyl and pethidine, or over-the-counter—for example, codeine. 
They do not include illicit opioids, such as heroin. There has been a substantial increase in 
the prescribing of pharmaceutical opioids in Australia in recent years—this increase may be 
a result of the ageing population in Australia or reflect a more widespread, clinical 
 32 Alcohol and other drug treatment services in Australia 2013–14 
acceptance of the use of pharmaceutical opioids for the treatment of pain (Nicholas et al. 
2011). 
In 2013–14, as a group, licit opioids (including codeine, morphine, buprenorphine 
methadone, oxycodone and other opioids) were the principal drug of concern in 4% of 
episodes (Table SD.1).  
Oxycodone is a pharmaceutical opioid (whether prescribed for the person or obtained 
illicitly) used to help control pain and is an alternative to morphine. There has been a large 
growth in oxycodone prescriptions in Australia over the last decade, with an increase of 
around 152% in the 6 years spanning 2002–03 to 2007–08 (Roxburgh et al. 2011).  
While the proportion of episodes with licit opioids as a principal drug of concern has 
remained relatively stable over the 5 years to 2013–14, there has been a considerable increase 
in the number of episodes for people receiving treatment for their own drug use where 
oxycodone was a principal drug of concern (from 418 episodes to 1,404). In 2013–14, 
oxycodone comprised the third highest proportion (18%) of treatment episodes where licit 
opioids were the principal drug of concern (after methadone, 23%, and morphine, 21%) 
(Table SD.3). This proportion has grown from 5% in 2009–10 and has coincided with a 
decrease in the proportion of episodes with morphine or methadone as a principal drug of 
concern. This may be a short-term trend, as attempts to limit supply of licit opioids is leading 
to an increase in illicit opioid use and injecting in the United States and more widely 
internationally. 
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5 Treatment provided 
There are a number of treatment types available to assist people with problematic drug use 
in Australia. Most aim to reduce the harm of drug use, while others use a structured drug-
free setting with abstinence-oriented interventions. This chapter provides information on the 
treatment types provided by publicly funded AOD treatment agencies in Australia. 
Information on clients and treatment agencies is included in the AODTS NMDS when a 
treatment episode provided to a client is closed (see Box 2.1). Treatment is available to assist 
people to address their own drug use, and to support the family and friends of people using 
drugs. 
5.1 Key facts 
In 2013–14: 
• Counselling was the most common treatment type (43%). 
• The most common source of referral for treatment episodes was self/family (43%). 
• Around 4 in 5 (79%) closed treatment episodes ended within 3 months. 
• The median duration of closed treatment episodes was about 3 weeks (23 days). 
• Around 2 in 3 (64%) closed treatment episodes had an expected cessation. 
• Most of the treatment episodes provided to clients for their own drug use were for 
male clients (67%), whereas most clients seeking support for someone else’s drug use 
were female (64%). 
• Clients seeking support for someone else’s drug use tended to be older—half (51%) of 
the episodes were provided to clients aged over 40, compared with over two-thirds 
(68%) of clients seeking treatment for their own drug use who were aged 10–39. 
Over the 5-year period to 2013–14: 
• The proportion of episodes for each main treatment type has remained fairly stable, 
with counselling, withdrawal management and assessment only being the most 
common types of treatment. 
• The median duration of closed episodes for the client’s own drug use increased from 
22 days to 23 days, peaking at 25 days in 2011–12. 
• The proportion of episodes with an expected cessation has decreased slightly, from 
68% to 64%. 
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5.2 Characteristics of clients and episodes 
In 2013–14, 114,851 clients (client records with a valid SLK) received 180,713 treatment 
episodes from AOD treatment agencies. Most (95%) of the clients were seeking treatment for 
their own drug use—a total of 108,972 clients (or 95% of episodes)—and most of these were 
male (69% of clients and 67% of episodes). Conversely, clients seeking support for someone 
else’s drug use were more likely to be female (64%) (tables SC.1, SC.28 and SE.2). 
Around 1 in 7 (14%) treatment episodes were provided to Indigenous Australians in 2013–14. 
This proportion was consistent for clients receiving treatment for their own drug use (14%), 
while for clients receiving support for someone else’s drug use, 9% of treatment episodes 
were provided to Indigenous Australians (Table SE.4). 
In 2013–14, more than half (54%) of clients seeking treatment were aged 20–39 (55% of 
episodes). Clients seeking support for someone else’s drug use tended to be older—half 
(51%) of these treatment episodes were provided to clients aged 40 and over, compared with 
just under one-third (32%) of episodes for those receiving treatment for their own drug use 
(Table SC.2 and SE.5). 
Nationally in 2013–14, just over two-thirds (69%) of closed treatment episodes were provided 
in Major cities, 19% in Inner regional areas and 10% in Outer regional areas. Relatively few 
treatment episodes were provided in Remote or Very remote areas (3%). 
 
(a) Based on client records with a valid SLK. 
Source: Table SC.28. 
Figure 5.1: Clients receiving treatment in both years, 2012–13 and 2013–14 
In 2013–14, most (86%) clients received treatment at 1 agency, 11% at 2, and 2% of clients 
received treatment at 3 or more agencies. Nationally, the number of clients presenting to 
publicly funded AOD services increased between 2012–13 and 2013–14. A total of 190,617 
clients received treatment over these two years. Of these, 39.7% (75,766 clients) presented in 
2012–13 only, 47.2% (90,053) presented in 2013–14 only, and 13.0% (24,798) received 
treatment in both years (Figure 5.1). 
One-fifth (21.6%) of the total 114,851 clients receiving treatment in 2013–14, also received 
treatment in 2012–13. 
39.7% in 
2012–13 only
Total number of 
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5.3 Referral to treatment 
Nationally in 2013–14, the most common source of referral for both clients receiving 
treatment for their own drug use and those receiving support for someone else’s drug use 
was self/family (42% and 63% respectively). Referral from a health service was also common 
for both client groups (26% and 18% respectively). Referrals from police or court diversion 
programs accounted for 17% of episodes for clients receiving treatment for their own drug 
use (Table ST.13–14). Clients referred by diversion programs tended to be younger; 23% of 
these episodes were for clients aged 10–19 and 37% were for clients aged 20–29, compared 
with 13% and 27%, respectively, for all episodes (Table SE.13). 
Over the 5 years from 2009–10, the proportion of episodes provided to clients for their own 
drug use where the client was referred by self/family increased from 37% to 42%. Over the 
same 5-year period, for clients receiving support for someone else’s drug use, there was a 
decline in those episodes where health services were the source of referral (from 23% to 
18%), and a rise in the proportion of referrals by self/family (from 60% to 63%) (Table SE.12). 
Table 5.1: Closed episodes by principal drug of concern and source of referral, 2013–14 (per cent) 
Principal drug of concern Self/family Health service Corrections Diversion Other Total 
Analgesics       
Codeine 54 38 1 2 6 100 
Morphine 53 31 7 4 5 100 
Buprenorphine 47 36 10 2 5 100 
Heroin 50 21 10 14 6 100 
Methadone 46 38 5 4 6 100 
Total analgesics 51 26 8 9 6 100 
Sedatives and hypnotics      
Alcohol 47 31 7 7 8 100 
Benzodiazepines 48 36 3 8 5 100 
Total sedatives and 
hypnotics 47 31 7 7 7 100 
Stimulants and hallucinogens     
Amphetamines 43 21 8 21 7 100 
Ecstasy 16 5 6 71 3 100 
Cocaine 45 13 8 27 7 100 
Nicotine 25 21 3 42 10 100 
Total stimulants and 
hallucinogens 40 21 7 24 7 100 
Cannabis 31 21 8 33 7 100 
Volatile solvents 22 34 4 19 21 100 
Source: AIHW analysis of the AODTS NMDS. 
In 2013–14, source of referral varied according to clients’ principal drugs of concern. Self/ 
family was the most common source of referral for clients receiving treatment for the 
principal drug of heroin (50% of episodes), alcohol (47% of episodes) and amphetamines 
(43% of episodes) (Table 5.1). Where cannabis was the principal drug of concern, diversion 
(33% of episodes) was the most common source of referral, followed by self/family (31% of 
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episodes) (see also Figure 4.7 in Chapter 4). Clients receiving treatment for alcohol as their 
principal drug of concern were less likely to be referred through diversion (7%) and more 
likely to be referred from a health service (31%), when compared with clients receiving 
treatment for heroin, amphetamines or cannabis. Around 7 in 10 (71%) treatment episodes 
for clients whose principal drug of concern was ecstasy were referred to treatment through 
police or court diversion programs (see Chapter 4 for further information). 
Over the 5 years to 2013–14, the proportion of episodes where the client was referred by  
self /family increased from 38% to 43%. Episodes where alcohol was the principal drug of 
concern had the greatest increase in self/family as the source of referral, from 40% to 47% 
over the same period. The proportion of episodes where the client was referred by a health 
service decreased slightly from 27% in 2009–10 to 25% in 2013–14. However for the episodes 
where amphetamines were the principal drug of concern, the proportion of clients referred 
by a health service increased, from 19% to 21%, peaking in in 2010–11 at 22%. Over the same 
period, referrals from diversion programs decreased (from 18% to 16%) (Table SE.11).  
5.4 Length of treatment 
In 2013–14, around 4 in 5 (80%) closed episodes ended within 3 months (80% for clients 
receiving treatment for their own drug use and 80% for someone else’s drug use, see sections 
5.5 to 5.6 for further information). Over the 5 years to 2013–14, the proportion of episodes for 
the client’s own drug use that ended within 3 months remained fairly stable (around 79%) 
(Table SE.18). 
Nationally, the median duration of closed episodes for the client’s own drug use was just 
over 3 weeks (23 days), and just under 5 weeks (33 days) for clients receiving support for 
someone else’s drug use. The median duration of closed episodes for the client’s own drug 
use increased slightly over the 5 years from 2009–10 from 22 days to 23 days in 2013–14, 
peaking at 25 days in 2011–12. This increase over time is largely due to increases in the 
median duration of episodes with a main treatment type of counselling, rehabilitation or 
‘other’ (Table SE.19). 
5.5 Treatment completion 
Reasons for clients ceasing to receive a treatment episode from an AOD treatment service 
include expected cessations (for example, treatment was completed), unexpected cessations 
(for example, non-compliance) and administrative cessation (for example, client transferred 
to another service provider) (see the Glossary and Box 2.1 for further details). In 2013–14, 
around 3 in 5 (64%) completions for the client’s own drug use recorded a reason for cessation 
in the ‘expected’ category. Unexpected cessations accounted for one-fifth (20%), other 
reasons around 9% and administrative cessations 6%. This pattern was broadly similar for 
completions for clients who received support for someone else’s drug use (Table 5.2). 
In 2013–14, treatment episodes with an expected cessation were highest where ecstasy was 
the principal drug of concern (87%), followed by nicotine (82%), and cocaine and cannabis 
(both 70%). The lowest proportion of expected cessations was for episodes with 
buprenorphine as the principal drug of concern (45%). As a group, analgesics tended to have 
the lowest proportion of closed episodes with an expected cessation (55%) (Table 5.3).  
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Table 5.2: Closed episodes by reason for cessation and client type, 2013–14 (per cent) 
Reason for cessation Own drug use Other’s drug use 
Expected cessation 64.3 63.4 
Unexpected cessation 20.4 12.9 
Administrative cessation 6.0 4.0 
Other 9.3 19.8 
Total 100.0 100.0 
Source: Table SE.14. 
One-quarter (25%) of treatment episodes where amphetamines were the principal drug of 
concern had an unexpected cessation, followed by morphine (23%) and codeine (22%), while 
ecstasy had the lowest proportion (8%) of unexpected cessations (Table 5.3). As a group, 
stimulants and hallucinogens had the highest proportion of episodes with an unexpected 
cessation (23%). 
Table 5.3: Closed episodes by principal drug of concern and reason for cessation, 2013–14 (per cent) 







cessation Other Total 
Analgesics      
Codeine 58 22 15 5 100 
Morphine 46 23 19 12 100 
Buprenorphine 45 17 26 11 100 
Heroin 57 20 8 15 100 
Methadone 60 15 15 10 100 
Total analgesics 55 20 12 12 100 
Sedatives and hypnotics     
Alcohol 64 21 6 9 100 
Benzodiazepines 62 18 10 10 100 
Total sedatives and 
hypnotics 64 21 6 9 100 
Stimulants and hallucinogens     
Amphetamines 62 25 5 8 100 
Ecstasy 87 8 1 4 100 
Cocaine 70 20 5 5 100 
Nicotine 82 10 3 5 100 
Total stimulants and 
hallucinogens 65 23 5 7 100 
Cannabis 70 19 4 7 100 
Volatile solvents 67 17 5 11 100 
Source: AIHW analysis of the AODTS NMDS. 
Over the 5 years to 2013–14, treatment episodes that ended in an expected cessation have 
decreased overall (by 4%) (Table SD.16). The decrease in expected cessation was greatest for 
episodes where heroin was the principal drug of concern (5%), followed by alcohol (4%) and 
amphetamines and cannabis (both 3%). Over the same time period, unexpected cessation 
increased by 1% for episodes with alcohol, amphetamines and cannabis as the principal drug 
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of concern, and decreased by 1% for episodes where heroin was the principal drug of 
concern (Table SD.16). 
Over the 5 years to 2013–14, episodes where alcohol and cannabis were the principal drug of 
concern were consistently most likely to have expected cessations, although the proportion 
of these episodes declined slightly (from 68% to 64%, with a high of 69% in 2010–11, and 73% 
to 70% respectively) (Table SD.16). 
Over the same period, there was a slight decrease in the proportion of episodes where 
amphetamines were the principal drug of concern ending in an expected cessation (from 65% 
to 62%), and slight increase in episodes ending in an unexpected cessation (from 24% to 25%) 
(Table SD.16). 
The proportion of episodes with an expected cessation or an unexpected cessation where 
heroin was the principal drug of concern both declined (from 62% to 57%, with a low of 53% 
in 2012–13, and 21% to 20% respectively) (Table SD.16).  
5.6 Treatment types 
Counselling was the most common treatment type provided to all clients in 2013–14 (46%), 
followed by assessment only (16%), information and education only (11%) and withdrawal 
management (10%). This pattern was consistent for both client groups (that is, clients 
receiving treatment for their own drug use and clients receiving support for someone else’s 
drug use) (Table SC.13). 
In 2013–14, clients seeking treatment for their own drug use were more likely to be aged 
between 20–49 for all treatment types (ranging between 75–87%), with the exception of 
support and case management only and information and education only, where clients were 
more likely to be aged between 10–39 (77% and 83% respectively) (Figure 5.2). The age of 
clients was more varied for those seeking support for someone else’s drug use. Clients 
receiving counselling and information and education only were most likely to be aged 40 or 
older (62% and 58% respectively), while clients receiving support and case management only 
were most likely to be 10–39 years (60%) (Figure 5.2). 
In 2013–14, the most common source of referral for clients was self/family (39%). This was 
consistent for all treatment types, with the exception of information and education only, 
where diversion was the most common source of referral (75%) (Table SC.16). 
Nearly two-thirds (63%) of clients had an expected cessation (for example, their treatment 
was completed). This varied by treatment type—from 42% of clients receiving rehabilitation 
to 94% of those clients receiving information and education only (Table SC.18). 
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Source: Table ST.4.  
Figure 5.3: Closed episodes provided by client type and main treatment type, 2003–04 to 2013–14 
Overall since 2003–04, the proportion of episodes for each main treatment type has remained 
fairly stable, with counselling, withdrawal management and assessment only being the most 
common types of treatment. Counselling continues to be the most common main treatment 
type provided (comprising about 2 in 5 episodes since 2003–04). In 2012–13, assessment only 
replaced withdrawal as the second most common main treatment type. While this pattern of 
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main treatment type is consistent for clients seeking treatment for their own drug, for those 
seeking support for someone else’s drug use, counselling, information and education only 
and support and case management only have remained the most common main treatment 
types over the same period (Figure 5.3). 
For clients seeking treatment for their own drug use, there has been an overall increase since 
2003–04 in the proportion of episodes with counselling as the main treatment type (from 35% 
to 41%), and a decrease in those episodes with withdrawal management as the main 
treatment type (from 21% to 15%). For clients seeking support for someone else’s drug use 
there has been an overall decrease over the same time period in the proportion of episodes 
with counselling as the main treatment type (from 80% to 70%), and a slight increase in those 
episodes with support and case management only as the main treatment type (from 5% to 
8%) (Table ST.4). 
Counselling was the most common treatment type in all regions. Withdrawal management 
(detoxification) was more common in Major cities than in other areas. The lowest number of 
treatment episodes for withdrawal management and rehabilitation were in Very remote areas 
(Table SA.9).  
Of the main treatment types that were available to both clients receiving treatment for their 
own drug use and to those receiving support for someone else’s drug use, most episodes 
were for clients receiving treatment for their own drug use—ranging from 92% for 
counselling to 98% for assessment only (Figure 5.4). 












































Clients receiving treatment for their own drug use
70,819 (92%)
Clients receiving treatment for someone else’s drug use
6,287 (8%)
Clients receiving treatment for their own drug use
25,612 (100%)
Clients receiving treatment for their own drug use
27,630 (98%)
Clients receiving treatment for someone else’s drug use
553 (2%)
Clients receiving treatment for their own drug use
15,996 (96%)
Clients receiving treatment for someone else’s drug use
719 (4%)
Clients receiving treatment for their own drug use
3,351 (87%)
Clients receiving treatment for someone else’s drug use
503 (13%)
Clients receiving treatment for their own drug use
10,142 (100%)
Clients receiving treatment for their own drug use
14,813 (94%)
Clients receiving treatment for someone else’s drug use
893 (6%)
Clients receiving treatment for their own drug use
3,395 (100%)
 
Sources: Tables ST.2 and ST.4. 
Figure 5.4: Summary treatment characteristics (main and additional) of closed episodes, 2013–14 
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Counselling 
Counselling is the most common treatment type for problematic alcohol and/or other drug 
use and can include cognitive behaviour therapy, brief intervention, relapse intervention and 
motivational interviewing (ADCA 2013). In 2013–14, 2 in 5 (41%) episodes provided to 
clients for their own drug use, and almost 1 in 7 (70%) episodes provided to clients for 
someone else’s drug use, had a main treatment type of counselling (Table ST.3). Younger 
males were more likely to receive counselling for their own drug use—66% of closed 
treatment episodes were for males, and 41% of these episodes were provided to those aged 
10–29. Clients receiving counselling for someone else’s drug use were more likely to be 
female (65% of episodes) and aged over 40 years (63% of episodes) (Table ST.19). 
For those clients seeking treatment for their own drugs use, 1 in 7 (14%) closed treatment 
episodes with a main treatment type of counselling were for Indigenous clients. For episodes 
where clients received support due to someone else’s drug use, 7% of clients identified as 
Indigenous Australians (Table ST.21). 
For both client types, more than one-third of episodes with a main treatment type of 
counselling lasted 1–3 months (35% for own drug use and 36% for someone else’s use), while 
nearly one-quarter (20% and 23% respectively) lasted 2–29 days (Table ST.26).  
For clients receiving treatment for their own drug use, over the 5 years from 2009–10, the 
proportion of episodes ending within 1 month decreased slightly (from 36% to 32%), while 
the proportion of episodes lasting more than 1 month increased (from 63% to 67%) (Table 
ST.27). Over the same period, for clients receiving support for someone else’s drug use, the 
proportion of closed episodes lasting 1–3 months increased slightly (from 36% to 37%), while 
the proportion lasting 12 months or more decreased (from 7% to 3%) (Table ST.27). 
Assessment only 
While all service providers would normally include an assessment component in all 
treatment types, these are treatment episodes for which only an assessment is provided to 
the client. In 2013–14, 16% of treatment episodes provided to clients for their own drug use, 
and 6% of episodes provided to clients for someone else’s drug use, had a main treatment 
type of assessment only (Table ST.3).  
Younger males were more likely to receive assessment only for their own drug use—68% of 
closed treatment episodes, with 58% of these episodes provided to those aged 20–39. Clients 
receiving assessment only for someone else’s drug use were more likely to be female (53%) 
and aged 40 and over (52%) (Table ST.41). 
Over the 5 years from 2009–10, for clients seeking treatment for their own drug use, the 
proportion of treatment episodes for clients aged 10–19 increased from 7% to 9%, while the 
proportion for those aged 20–29 decreased from 34% to 28%. For those clients seeking 
support for someone else’s drug use, there was a decrease in the proportion of episodes 
provided to older clients. Nearly two-thirds (60%) of episodes were provided to clients aged 
40 and over in 2009–10 compared with 44% in 2013–14 (Table ST.42). 
Where the main treatment type was assessment only, 14% of closed treatment episodes for 
clients’ own drug use were for Indigenous clients, and 12% of clients seeking support for 
some else’s drug use identified as Indigenous Australians (Table ST.43). 
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The majority of treatment episodes for clients lasted just 1 day—54% of episodes for clients 
seeking treatment for their own drug use, and 81% of episodes those seeking support for 
someone else’s drug use (Table ST.45). 
Over the 5 years from 2009–10, the proportion of closed episodes ending within 1 day 
increased (from 45% to 54% for clients own use, and 77% to 81% for someone else’s drug 
use), while the proportion of episodes lasting 2–29 days decreased (from 32% to 31%, and 
10% to 7% respectively). The proportion of episodes in all other duration groups (from 1–3 
months to more than 12 months) also decreased over the same time period, with the 
exception of those clients seeking treatment for their own drug use, where the proportion of 
episodes ending within 1 to less than 6 months increased from 3% to 7% (Table ST.46). It is 
important to note that these trends are influenced by differences in jurisdictional service 
delivery practices and data quality improvement over time. 
Withdrawal management 
Withdrawal management (detoxification) includes medicated and non-medicated treatment 
to assist in managing, reducing or stopping the use of a drug of concern. In 2013–14, 15% of 
closed treatment episodes provided to clients for their own drug use had a main treatment 
type of withdrawal management (Table ST.3). (Note that this type of treatment is not 
available for clients seeking support for someone else’s drug use.) Two-thirds (64%) of these 
episodes were provided to male clients, and over 1 in 12 (8%) were for Indigenous clients 
(tables ST.30 and ST.32). 
Most (54%) of the treatment episodes provided for withdrawal management were for those 
aged 30–39 (29%) and 40–49 (25%). Just over four-fifths (83%) lasted less than 30 days (tables 
ST.31 and ST.37).  
Over the 5 years from 2009–10, there has been an increase in the proportion of episodes 
provided to older clients where withdrawal management was the main treatment type. In 
2009–10, 39% of episodes were for clients aged 40 and over, compared with 43% in 2013–14 
(Table ST.31). 
Support and case management only 
Support includes activities such as helping a client who occasionally calls an agency worker 
for emotional support. Case management is usually more structured than ‘support’. It can 
assume a more holistic approach, taking into account all client needs including general 
welfare needs, and it includes assessment, planning, linking, monitoring and advocacy 
(Vanderplaschen et al. 2007). In 2013–14, 9% of episodes provided to clients for their own 
drug use, and 8% of episodes provided to clients for someone else’s drug use, had a main 
treatment type of support and case management only (Table ST.3). 
Almost two-thirds (63%) of the closed treatment episodes provided to clients for their own 
drug use were for male clients, just over half (54%) were aged 10–29, and 19% were for 
Indigenous clients. Female clients were more likely to be Indigenous than male clients  
(24% compared with 16%) (tables ST.50–51).  
For those clients seeking support for someone else’s drug use, 61% of treatment episodes 
were for female clients, half (51%) were aged 10–19, and almost 1 in 12 (8%) were for 
Indigenous clients. Female clients were more likely to be Indigenous than male clients  
(4% compared with 10%) (tables ST.50–51). 
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Over the 5 years from 2009–10, there has been an increase in the proportion of episodes 
provided to older clients. For both client groups, those aged 10–19 decreased (from 31% to 
25% of episodes for clients receiving treatment for their own drug use, and 74% to 51% for 
clients receiving support for someone else’s drug use), and those aged 50 and over increased 
(from 5% to 9% for clients seeking treatment for their own drug use, and from 5% to 21% for 
clients receiving support for someone else’s drug use) (Table ST.50). 
Most (54%) of the treatment episodes provided to clients for their own drug use with a main 
treatment type of support and case management only were provided to those in the 10–19 
(25%) and 20–29 (29%) age groups. Nearly two-thirds (61%) of episodes for the client’s own 
drug use lasted between 2–29 days (26%) and 1–3 months (35%). Clients seeking support for 
someone else’s drug use tended to be younger (51% were 10–19), and spend longer in 
treatment, with 41% of episodes lasting between 1–3 months (tables ST.50 and ST.54). 
Over the 5 years from 2009–10, the duration of treatment episodes for clients seeking 
treatment for their own drug use remained relatively stable. Conversely, for clients seeking 
support for someone else’s drug use, the proportion of closed episodes lasting 1–3 months 
and 2–29 days have changed substantially. The proportion of episodes lasting 1–3 months 
increased from 30% to 41% and those lasting 2–29 days decreased from 49% to 36% (Table 
ST.56. 
Information and education only 
In 2013–14, around 1 in 10 episodes provided to clients had a main treatment type of 
information and education only (9% of episodes for client’s own drug use and 10% of 
episodes for someone else’s) (Table ST.3). 
Clients receiving information and education only for their own drug use were more likely to 
be male (73%) and younger (29% of episodes were for clients aged 10–19 and 35% for clients 
aged 20–29). Clients receiving information and education only for someone else’s drug use 
were more likely to be female (79%) and younger (54% of episodes were provided to clients 
aged 10–19). The age of all clients seeking treatment remained relatively stable over the 5 
years from 2009–10 (tables ST.57–58).  
Similar rates of closed treatment episodes were provided to clients who identified as 
Indigenous Australians—13% of closed treatment episodes for those clients seeking 
treatment for their own drug use, and 11% of clients seeking support for some else’s drug 
use (Table ST.59). 
As expected for this type of treatment, the majority of episodes for clients lasted just 1 day—
82% of episodes for clients seeking treatment for their own drug use, and 70% of episodes for 
those seeking support for someone else’s drug use (Table ST.61). 
Over the 5 years from 2009–10, the duration of treatment episodes for those clients seeking 
treatment for their own drug use remained relatively stable. Over the same period, for those 
seeking treatment for someone else’s drug use, the proportion of episodes lasting 1 day 
increased (from 50% to 70%, peaking at 85% in 2010–11) while the opposite is true for 
episodes lasting 2–29 days (declining from 25% to 12%) (Table ST.62). 
Rehabilitation 
Rehabilitation focuses on supporting clients in stopping their drug use and helping to 
prevent psychological, legal, financial, social and physical consequences of problematic drug 
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use. Rehabilitation can be delivered in a number of ways including, residential treatment 
services, therapeutic communities and community-based rehabilitation services (AIHW 
2011). In 2013–14, 6% of closed treatment episodes provided to clients for their own drug use 
had a main treatment type of rehabilitation. (Note that this type of treatment is not available 
for clients seeking support for someone else’s drug use.) Almost two-thirds (65%) of these 
episodes were provided to male clients, and almost one-fifth (17%) were for Indigenous 
clients (tables ST.3, ST.65 and ST.67). 
Three in 5 (63%) of the treatment episodes provided for rehabilitation were for those aged 
20–29 (28%) and 30–39 (35%). More than one-third (34%) of the episodes lasted from 1–3 
months, while a further 33% lasted 2–29 days (tables ST.66 and ST.73).  
Over the 5 years from 2009–10, the duration of closed episodes for those clients seeking 
treatment for their own drug use remained relatively stable. There has been little variation in 
the age proportions over the 5 years from 2009–10 (tables ST.66 and ST.76). 
Pharmacotherapy 
Pharmacotherapy is the replacement of a person’s drug of choice with a legally prescribed 
and dispensed substitute. Pharmacotherapy programs are available for a range of drugs, 
including alcohol and opioids. Where a pharmacotherapy is used for withdrawal, it is 
included in the ‘withdrawal’ category. Due to the complexity of the pharmacotherapy sector, 
this report provides only limited information on agencies whose sole function is to provide 
pharmacotherapy. Only episodes where pharmacotherapy was an additional treatment, or 
where it was the main treatment and an additional treatment was provided, are included in 
the AODTS NMDS. Episodes where pharmacotherapy was the main treatment and no 
additional treatment was provided are excluded. Pharmacotherapy is only available to 
clients receiving treatment for their own drug use. As most pharmacotherapy services are 
outside the scope of the AODTS NMDS, the information presented on pharmacotherapy 
episodes are a significant underrepresentation. More comprehensive information on opioid 
pharmacotherapy treatment provided in Australia is available from the AIHW’s National 
Opioid Pharmacotherapy Statistics <http://www.aihw.gov.au/alcohol-and-other-
drugs/nopsad/> Annual Data (NOSPAD) collection. 
For those services that were within scope of the AODTS NMDS, nationally in 2013–14, 2% of 
treatment episodes were provided with a treatment type of pharmacotherapy (main or 
additional). In just over one-third (34%) of these episodes, pharmacotherapy was an 
additional treatment (tables ST.3 and ST.75). 
Of the closed episodes where pharmacotherapy was the main treatment type, more than 
one-quarter (27%) lasted up to 1 month, while a further 20% lasted 1–3 months (Table ST.83). 
Three-fifths (61%) of treatment episodes with a main treatment type of pharmacotherapy 
were provided to male clients, and 12% were for Indigenous clients. Two-thirds (66%) of 
these episodes were for those aged 30–39 (41%) and 40–49 (25%) and. A further 22% were for 
clients aged 20–29; just 2% were for clients aged 60 and over (tables ST.76–78). 
Of the treatment episodes provided to clients with a main treatment type of 
pharmacotherapy, more than one-third (36%) had heroin as a principal drug of concern, 
while almost 1 in 8 (13%) had a principal drug of alcohol. Methadone (11% of episodes) was 
also a common principal drug of concern (Table ST.79). 
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Appendix A: Data and methods 
Age 
Age is calculated as at the start of the episode. 
Duration 
Duration is calculated in whole days and calculated only for closed episodes. 
Drugs of concern 
The AODTS NMDS contains data on drugs of concern that are coded using the ABS’s 
Australian Standard Classification of Drugs of Concern 2011 (ASCDC) (ABS 2011a). In this 
report, these drugs are grouped (Table A1). 
Table A1: Groupings of drugs of concern 
Group ASCDC codes Category Includes 
Analgesics  1000–1999 Codeine   
  Morphine   
  Buprenorphine   
  Heroin   
  Methadone   
 Other opioids oxycodone, fentanyl, pethidine 
  Other analgesics paracetamol  
Sedatives and 
hypnotics  
2000–2999 Alcohol ethanol, methanol and other alcohols 
  Benzodiazepines clonazepam, diazepam and temazepam 
  Other sedatives and 
hypnotics 
ketamine, nitrous oxide, barbiturates and kava 
Stimulants and 
hallucinogens  
3000–3999 Amphetamines amphetamine, dexamphetamine and methamphetamine  
  Ecstasy (MDMA)   
  Cocaine   
  Nicotine   
  Other stimulants and 
hallucinogens 
volatile nitrates, ephedra alkaloids, phenethylamines, 
tryptamines and caffeine 
Cannabinoids 7000–7199 Cannabis  
Other 4000–6999 
9000–9999 
Other anabolic agents and selected hormones, antidepressants and 
antipsychotics, volatile solvents, diuretics and opioid 
antagonists 
Not stated 0000–0002 Not stated   
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Population rates 
In this publication, crude rates were calculated using the ABS estimated resident population 
(ERP) at the midpoint of the data range, that is, rates for 2013–14 data were calculated using 
the ERP at 31 December 2013. 
Reason for cessation 
The AODTS NMDS contains data on the episode end reason (reason for cessation). In this 
report, these end reasons are grouped (Table A2). Data for the individual end reasons are 
available in the online supplementary tables.  
A different method was used for grouping end reasons in reports released prior to 2014 and 
therefore trend comparisons across reports should be made with caution. It is possible to 
compare data at the individual end reasons using the supplementary tables. 
Table A2: Grouping of cessation reasons by indicative outcome type 
Outcome type Reason for cessation 
Expected cessation Treatment completed 
Ceased to participate at expiation 
Ceased to participate by mutual agreement 
Unexpected cessation Ceased to participate against advice 
Ceased to participate without notice 
Ceased to participate due to non-compliance 
Administrative cessation Change in main treatment type 
Change in delivery setting 
Change in principal drug of concern 
Transferred to another service provider 
Other Drug court or sanctioned by court diversion service 
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Remoteness 
This report uses the ABS’s Australian Statistical Geography Standard (ASGS) Remoteness 
Structure 2011 (ABS 2011b) to analyse the remoteness of AOD treatment agencies. This 
structure allows areas that share common characteristics of remoteness to be classified into 
broad geographic regions of Australia. These areas are: 
• Major cities  
• Inner regional  
• Outer regional  
• Remote  
• Very remote. 
The Remoteness Structure divides each state and territory into several regions on the basis of 
their relative access to services.  
Examples of places that are considered Major cities in the ASGS classification include 
Canberra and Newcastle. Hobart and Bendigo are Inner regional areas and Cairns and 
Darwin are Outer regional areas. Katherine and Mount Isa are Remote areas and Tennant 
Creek and Meekatharra are Very remote. 
For this report, the remoteness of the agency was determined using the Statistical Area (SA) 
level 2 (SA2) of the agency. Some SAs are split between multiple remoteness areas. Where 
this was the case, the data were weighted according to the proportion of the population of 
the SA in each remoteness area.  
The ASGS has replaced the Australian Standard Geographical Classification (ASGC) 2006 
(ABS 2006). Remoteness areas for previous reports were calculated under the ASGC. 
Therefore remoteness data for 2011–12 and previous years are not comparable to remoteness 
data for 2012–13 and subsequent years.  
Service sectors 
From 2008–09, agencies funded by the Australian Government Department of Health under 
the NGOTGP were classified as ‘non-government’ agencies. Before this, many of these 
agencies were classified as ‘government’ agencies. Trends in service sectors of agencies 
should be interpreted with caution.  
Trends 
Trend data may differ from data published in previous versions of Alcohol and other drug 
treatment services in Australia, due to data revisions. 
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Appendix B: Imputation methodology for 
AODTS clients 
From the inception of the AODTS NMDS, data have been collected only about treatment 
episodes provided by AOD treatment services. Data about the clients those episodes relate to 
have not been available at a national level. A statistical linkage key (SLK) was introduced 
into the AODTS NMDS for the 2012–13 collection to enable the number of clients receiving 
treatment to be counted, while continue to ensure the privacy of these individuals receiving 
treatment. In 2012–13 and 2013–14, an SLK was reported for the majority of episodes (90% 
and 96% respectively) (tables B1 and B2). 
An imputation strategy for the collection was developed to correct for the impact of invalid 
or missing SLKs on the total number of clients. This strategy takes into account a number of 
factors relating to the number of episodes per client and makes assumptions relating to 
spread across agencies. It also takes into consideration the likelihood that an episode with a 
missing SLK relates to a client that has already been counted through other episodes with a 
valid SLK. Further details on the imputation strategy are provided below. 
Using the imputation strategy to adjust for non-response and data quality issues, it is 
estimated there were 118,741 clients who received treatment in 2013–14. 
Table B1: Imputed numbers of clients, by states and territories, 2013–14 
 NSW Vic Qld WA SA Tas ACT NT Aust 
Number of episodes 42,406 56,392 36,093 20,867 13,085 2,841 4,652 4,377 180,713 
Number of episodes with valid SLKs 37,307 55,369 35,733 19,855 12,778 2,825 4,610 4,192 172,669 
Percentage of episodes with valid SLKs (%) 88.0 98.2 99.0 95.2 97.7 99.4 99.1 95.8 95.5 
Number of episodes with invalid SLKs 5,099 1,023 360 1,012 307 16 42 185 8,044 
Number of distinct clients (from valid SLKs) 24,184 29,548 28,960 15,146 9,195 2,432 3,309 2,870 114,851 
Imputed number of distinct clients 26,402 29,877 29,207 15,760 9,365 2,444 3,332 2,963 118,741 
Attributing number of clients to set of missing SLK records 
The AODTS NMDS collects information at the service record level. Service records are 
associated with individual clients by way of an SLK. There are a number of records that have 
missing or invalid SLK data which cannot be attributed to a client. This leads to an 
underreporting of the total number of clients using the services as some (but not all) of the 
records will belong to clients who are not observed via a valid SLK.  
This document describes the method of using the available data—after making a number of 
assumptions about the behaviour of the whole population—to impute the total number of 
clients. 
Imputation groups 
Imputation groups are formed to improve the performance of the imputation. The service 
records were grouped according to properties that are thought to influence the behaviour of 
clients and the quality of SLK data, and then the imputation was performed at this 
imputation group level. 
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Possible properties to group by include such things as location, provider size (measured by 
number of service records) and service type. The data are also grouped according to any 
sub-populations that are going to be reported upon, for example jurisdiction. 
The final imputation groups were formed by balancing the often-competing priorities of 
having homogenous groups and the need to have groups of sufficient size to ensure that the 
imputation is robust. 
Assumptions and approximations 
Assumption 1: randomness and independence 
This imputation method assumes that whichever service provider a client attends for each 
incidence of service is random and independent of any other incidents of service the client 
may have. It is further assumed that the validity or otherwise of the SLK recorded on each 
service record is random and independent of both the client and the service provider with 
which the record is associated.  
Assumption 2: distribution of the number of service records per client 
This method also assumes that the distribution of the number of records per client for all 
clients is similar to that observed using the sub-set of records with valid SLKs. 
Approximation 1: no client has more than 10 service records 
This imputation method uses the approximation that no client has more than 10 service 
records.  
In order to implement this approximation, any clients observed to have more than 10 service 
records were treated as if they had only 10 and the proportion of clients with 10 service 
records calculated accordingly. 
Notation 
We start by defining the notation used in this document. 
𝑁𝑡:  the (unknown) total number of clients 
𝑁𝑡
′:  the imputed total number of clients 
𝑁𝑆𝐿𝐾1:  the number of clients observed using the records with a valid SLK 
𝑃𝑆𝐿𝐾1:  the proportion of clients with at least 1 service record with a valid SLK 
𝑃𝑁𝑖:  the (unknown) proportion of clients with 𝑖 service records 
𝑃𝑁𝑖
′ :  the imputed proportion of clients with 𝑖 service records 
𝑃𝑁𝑖,𝑆𝐿𝐾1: the proportion of clients with 𝑖 service records as observed using records with 
valid SLKs 
𝑛𝑡:  the total number of service records 
𝑛𝑡|𝑁𝑡,𝑃𝑁𝑖: the number of service records given the total number of clients and the 
proportions of clients with 𝑖 service records, 𝑖 = 1,2, … 10 
𝑛𝑆𝐿𝐾1:  the number of service records with a valid SLK 
𝑛𝑆𝐿𝐾0:  the number of service records with an invalid SLK 
𝑝𝑆𝐿𝐾0:  the proportion of service records with an invalid SLK 
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Methodology 
Given Assumption 1 and Approximation 1, the proportion of clients who have at least 1 
service record with a valid SLK is 




𝑁𝑆𝐿𝐾1 = 𝑃𝑆𝐿𝐾1 × 𝑁𝑡 
so it follows that the total number of clients is  
𝑁𝑡 = 𝑁𝑆𝐿𝐾1𝑃𝑆𝐿𝐾1  
To resolve this equation for 𝑁𝑡 we require the values of the 𝑃𝑁𝑖. These are unknown given 
that we are unable to observe the whole population due to the records with invalid SLK 
values. This method imputes the unknown 𝑃𝑁𝑖 using numerical methods and then uses these 
values to impute 𝑁𝑡.  
The process starts with the distribution of number of records per client that were observed 
using the records with valid SLKs �𝑃𝑁𝑖,𝑆𝐿𝐾1�. These values are then adjusted so that the 
following conditions are met. 
Constraint 1  







The imputed proportion of clients with 1 service record is less than or equal to the observed 
equivalent proportion among clients with records with valid SLKs. That is, 
𝑃𝑁1
′ ≤ 𝑃𝑁1,𝑆𝐿𝐾1. 
This constraint is used because some of the clients observed to have only 1 record will, in 
fact, have additional records with invalid SLKs. It is unlikely that the true proportion of 
clients with 1 service record is higher than that observed using records with valid SLKs. 
Constraint 3 
The total number of service records that the imputed total number of clients and the imputed 
distribution of records per client imply is equal to the observed number of service records. 
That is 
𝑛𝑡|𝑁𝑡′,𝑃𝑁𝑖′ = 𝑁𝑡′�(𝑖 × 𝑃𝑁𝑖′ )10
𝑖=1
= 𝑛𝑡 . 
This constraint is used to ensure that the imputed values are consistent with the observed 
number of records. 
  Alcohol and other drug treatment services in Australia 2013–14 53 
Penalty function 
Under Assumption 2 we want to limit how much the imputed proportions differ from the 
proportions observed via the records with valid SLK data. To achieve this we use a penalty 
function that increases as the distance between the imputed and observed proportions 
increases. This function is defined to be 
𝑓�𝑃𝑁1,𝑆𝐿𝐾1,𝑃𝑁2,𝑆𝐿𝐾1, … ,𝑃𝑁10,𝑆𝐿𝐾1,𝑃𝑁1′ ,𝑃𝑁2′ , … ,𝑃𝑁10′ � = ��𝑃𝑁𝑖′ − 𝑃𝑁𝑖,𝑆𝐿𝐾1�2𝑃𝑁𝑖,𝑆𝐿𝐾110𝑖=1  
Using numerical methods the 𝑃𝑁1′ ,𝑃𝑁2′ , …𝑃𝑁10′  are chosen such that the penalty function is 
minimised, subject to the 3 constraints. 





′ �1 − 𝑝𝑆𝐿𝐾0𝑖 �10𝑖=1  
The resulting number is then rounded to the nearest integer. 
Discussion 
This imputation technique uses available information to impute the total number of clients. 
The methodology takes into account the proportion of records with invalid SLK data and the 
distribution of the number of service records per client as observed via the records with valid 
SLK data.  
It is apparent that the assumptions made do not hold for every client or service record. It is 
reasonable to expect that a client’s attendance at a service provider will be affected by 
location and any prior contact they had with a provider. It should also be noted that some 
service providers failed to collect SLK for any service record during the reference period. 
Despite the known cases where Assumption 1 does not hold, it is reasonable to hope that, 
across the population as a whole, the assumption is a reasonable representation of the 
populations of clients and service records. 
It is believed that the impact of Approximation 1 will be small because, given Assumption 1, 
the chance that a client with more than 10 service records is not observed via a record with a 
valid SLK is extremely small. The chance diminishes as the proportion of records with an 
invalid SLK decreases and across jurisdictions the highest proportion observed is about 0.3. 
It should also be noted that the largest proportion of clients with 10 or more service records 
observed in the data at the jurisdiction level was only 0.007. 
There are many different penalty functions that could be used in this imputation. The 
function used was chosen because, compared to the other penalty functions investigated, it 
produced imputed proportions that were generally as close or closer to the observed 
proportions. It also most consistently resulted in a distribution that was similar in shape to 
the observed distribution of the number of records per client. 
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Table B2: Comparison of population characteristics for valid SLK episodes and all episodes, by states and territories, 2013–14  
  NSW Vic Qld WA SA Tas ACT NT 
  Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % 
Client type 
                Own drug use 97.1 96.3 92.9 92.7 97.9 97.3 93.6 93.2 99.3 99.2 93.2 93.2 97.9 97.7 91.9 89.5 
Other's drug use 2.9 3.7 7.1 7.3 2.1 2.7 6.4 6.8 0.7 0.8 6.8 6.8 2.1 2.3 8.1 10.5 
Sex                                 
Male 65.8 65.4 63.7 63.6 68.3 68.0 64.6 64.2 70.2 69.8 65.2 65.2 64.6 64.3 66.5 66.1 
Female 34.2 34.6 36.2 36.3 31.7 32.0 35.4 35.8 29.8 30.2 34.8 34.8 35.4 35.7 33.4 33.9 
Not stated 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 
Indigenous status                               
Indigenous 12.5 13.1 6.6 6.6 16.9 17.0 19.8 19.3 12.5 12.4 8.3 8.3 12.2 12.1 62.4 62.5 
Non-Indigenous 85.2 84.5 86.4 86.5 78.1 77.9 80.2 80.5 68.3 68.6 86.7 86.6 81.8 81.4 36.8 36.7 
Not stated 2.4 2.5 6.9 6.9 5.0 5.1 0.0 0.2 19.2 19.0 5.0 5.1 6.1 6.5 0.8 0.8 
Age group (years)                               
10–19 6.6 5.8 13.0 12.8 15.0 15.1 15.1 15.6 11.1 11.0 14.2 13.3 17.0 17.1 21.8 19.2 
20–29 23.9 24.9 28.8 29.6 29.2 29.6 27.9 29.2 23.4 23.5 26.3 27.4 23.1 23.3 24.2 25.6 
30–39 30.4 31.4 26.0 26.6 25.4 25.6 28.3 29.3 29.9 29.9 27.7 28.4 27.5 27.6 28.4 29.7 
40–49 23.4 23.3 19.4 19.4 18.0 17.7 18.0 17.9 22.3 22.4 20.0 19.5 19.8 19.5 17.1 17.2 
50–59 11.5 11.0 9.0 8.3 8.6 8.3 7.7 6.5 9.5 9.4 8.9 8.4 9.4 9.0 6.7 6.6 
60 and over 4.2 3.6 3.8 3.1 3.8 3.6 3.0 1.6 3.8 3.8 2.9 2.6 3.3 3.0 1.8 1.6 
Unknown 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.5 0.0 0.2 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
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Glossary 
additional drugs: clients receiving treatment for their own drug use nominate a principal 
drug of concern that has led them to seek treatment and additional drugs of concern, of 
which up to 5 are recorded in the AODTS NMDS. Clients receiving treatment for someone 
else’s drug use do not nominate drugs of concern. 
additional treatment type: clients receive 1 main treatment type in each episode and 
additional treatment types as appropriate, of which up to 4 are recorded in the AODTS 
NMDS.  
administrative cessation: includes episodes that ended due to a change in main treatment 
type, delivery setting or principal drug of concern, or where the client was transferred to 
another service provider. 
alcohol: a central nervous system depressant made from fermented starches. Alcohol inhibits 
brain functions, dampens the motor and sensory centres and makes judgment, coordination 
and balance more difficult (NDARC 2010). 
amphetamines: stimulants that include methamphetamine, also known as 
methylamphetamine. Amphetamines speed up the messages going between the brain and 
the body. Common names are speed, fast, up, uppers, louee, goey and whiz. Crystal 
methamphetamine is also known as ice, shabu, crystal meth, base, whiz, goey or glass. 
Australian Standard Geographical Classification (ASGC): was used from 1984 to 2011 by 
the Australian Bureau of Statistics for the collection and dissemination of geographically 
classified statistics. The ASGC provided a common framework of statistical geography 
which enabled the production of statistics that were comparable and could be spatially 
integrated. 
Australian Statistical Geography Standard (ASGS): is the Australian Bureau of Statistics' 
new geographical framework effective from July 2011. The ASGS replaces the Australian 
Standard Geographical Classification (ASGC). 
benzodiazepines: also known as 'minor tranquillisers', are most commonly prescribed by 
doctors to relieve stress and anxiety and to help people sleep. Common names include 
Benzos, tranx, sleepers, downers, pills, serras (Serepax®), moggies (Mogadon®), normies 
(Normison®). 
client type: the status of a person in terms of whether the treatment episode concerns their 
own alcohol and/or other drug use or that of another person. Clients may seek treatment or 
assistance concerning their own alcohol and/or other drug use, or support and/or assistance 
in relation to the alcohol and/or other drug use of another person. 
closed treatment episode: a period of contact between a client and a treatment provider or 
team of providers. An episode is closed when treatment is completed, there has been no 
further contact between the client and the treatment provider for 3 months or treatment is 
ceased (see reason for cessation). 
cocaine: belongs to a group of drugs known as stimulants. Cocaine is extracted from leaves 
of the coca bush (Erythroxylum coca). Some of the common names for cocaine include C, coke, 
nose candy, snow, white lady, toot, Charlie, blow, white dust and stardust. 
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expected cessation: includes episodes where the treatment was completed, or where the 
client ceased to participate at expiation or by mutual agreement. 
ecstasy: the popular street name for a range of drugs containing the substance 
3, 4-methylenedioxymethamphetamine (MDMA)—a stimulant with hallucinogenic 
properties. Common names for ecstasy include Adam, Eve, MDMA, X, E, the X, XTC, the 
love drug. 
government agency: those that operate from the public accounts of the Australian 
Government or a state or territory government, are part of the general government sector, 
and are financed mainly from taxation. 
heroin: one of a group of drugs known as opioids, which are strong pain killers with 
addictive properties. Heroin and other opioids are classified as depressant drugs. It is also 
known as smack, skag , dope, H, junk, hammer, slow, gear, harry, big harry, horse, black tar, 
China white, Chinese H, white dynamite, dragon, elephant, boy, home-bake or poison. 
illicit drug use: includes: 
• the use of illegal drugs—a drug that is prohibited from manufacture, sale or possession 
in Australia, for example, cannabis, cocaine, heroin and ecstasy 
• misuse, non-medical or extra-medical use of pharmaceuticals—drugs that are available 
from a pharmacy, over-the-counter or by prescription, which may be subject to misuse, 
for example opioid-based pain relief medications, opioid substitution therapies, 
benzodiazepines, over-the-counter codeine, and steroids 
• use of other psychoactive substances—legal or illegal, potentially used in a harmful way, 
for example, kava, or inhalants such as petrol, paint or glue (but not including tobacco or 
alcohol) (MCDS 2011). 
licit drug use: the use of legal drugs in a legal manner, and includes tobacco smoking and 
alcohol consumption (MCDS 2011). 
main treatment type: the principal activity that is determined at assessment by the treatment 
provider to treat the client’s alcohol or other drug problem for the principal drug of concern. 
median: the midpoint of a list of observations ranked from the smallest to the largest. 
nicotine: the highly addictive stimulant drug in tobacco. 
non-government agency: receive some government funding but are not controlled by the 
government, are directed by a group of officers or an executive committee, and may be an 
income tax-exempt charity. 
principal drug of concern: the main substance that the client stated led them to seek 
treatment from an alcohol and drug treatment agency. 
reason for cessation: the reason for the client ceasing to receive a treatment episode from an 
alcohol and other drug treatment service; these are: 
• ceased to participate against advice: where the service provider is aware of the client’s 
intention to stop participating in treatment, and the client ceases despite advice from 
staff that such action is against the client’s best interest 
• ceased to participate at expiation: where the client has fulfilled their obligation to satisfy 
expiation requirements (for example, participation in a treatment program to avoid 
having a criminal conviction being recorded against them) as part of a police or court 
diversion scheme and chooses not to continue with further treatment 
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• ceased to participate by mutual agreement: where the client ceases participation by 
mutual agreement with the service provider, even though the treatment plan has not 
been completed. This may include situations where the client has moved out of the area 
• ceased to participate involuntarily: where the service provider stops the treatment due 
to non-compliance with the rules or conditions of the program 
• ceased to participate without notice 
• change in the delivery setting 
• change in the principal drug of concern 
• change in the main treatment type 
• death 
• drug court or sanctioned by court diversion service: where the client is returned to 
court or jail due to non-compliance with the program 
• imprisoned (other than sanctioned by a drug court or diversion service) 
• treatment completed: where the treatment was completed as planned 
• transferred to another service provider: this includes situations where the service 
provider is no longer the most appropriate and the client is transferred or referred to 
another service. For example, transfers could occur for clients between non-residential 
and residential services or between residential services and a hospital. Excludes 
situations where the original treatment was completed before the client transferred to a 
different provider for other treatment. 
referral source: the source from which the client was transferred or referred to the alcohol 
and other drug treatment service. 
standard drink: contains 10 grams of alcohol (equivalent to 12.5 millilitres of alcohol). Also 
referred to as a full serve. 
treatment type: the type of activity that is used to treat the client’s alcohol or other drug 
problem; these are: 
• assessment only: where only assessment is provided to the client. Note that service 
providers would normally include an assessment component in all treatment types 
• counselling: is the most common treatment for problematic alcohol and/or other drug 
use and can include cognitive behaviour therapy, brief intervention, relapse intervention 
and motivational interviewing (ADCA 2013) 
• information and education only 
• pharmacotherapy, where the client receives another type of treatment in the same 
treatment episode: includes drugs such as naltrexone, buprenorphine and methadone 
used as maintenance therapies or relapse prevention for people who are addicted to 
certain types of opioids. Where a pharmacotherapy is used for withdrawal, it is included 
in the ‘withdrawal’ category. Due to the complexity of the pharmacotherapy sector, this 
report provides only limited information on agencies whose sole function is to provide 
pharmacotherapy 
• rehabilitation: focuses on supporting clients in stopping their drug use and helping to 
prevent psychological, legal, financial, social and physical consequences of problematic 
drug use. Rehabilitation can be delivered in a number of ways including residential 
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treatment services, therapeutic communities and community-based rehabilitation 
services (AIHW 2011)  
• support and case management only: support includes activities such as helping a client 
who occasionally calls an agency worker for emotional support. Case management is 
usually more structured than ‘support’. It can assume a more holistic approach, taking 
into account all client needs including general welfare needs, and it includes assessment, 
planning, linking, monitoring and advocacy (Vanderplaschen et al. 2007) 
• withdrawal management (detoxification): includes medicated and non-medicated 
treatment to assist in managing, reducing or stopping the use of a drug of concern. 
tobacco: see nicotine. 
treatment episode: the period of contact between a client and a treatment provider or a team 
of providers. Each treatment episode has 1 principal drug of concern and 1 main treatment 
type. If the principal drug or main treatment changes, then a new episode is recorded. 
unexpected cessation: includes episodes where the client ceased to participate against 
advice, without notice or due to non-compliance. 
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Alcohol and other drug treatment 
services in Australia 2013–14
Around 119,000 clients were estimated to have received over 
180,700 treatment episodes from 795 publicly funded alcohol 
and other drug treatment agencies in 2013-14. Alcohol was 
the most common drug leading clients aged 30 and over to 
seek treatment, while cannabis was most common for clients 
aged 10–29. over the 5 years from 2009–10, there has been an 
increase in the proportion of episodes where amphetamines 
were the principal drug on concern (from 7% to 17%) and an 
increase in smoking/inhaling as the method of administration for 
amphetamines. A majority of treatment episodes had a duration 
of three months or less, and counselling remains the most 
common treatment type.
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